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ABSTRACT 
 
PATRICK C. GULEY:  Serum Albumin as a Carrier of Immunostimulatory Oligonucleotides 
for Cancer Therapy 
(Under the direction of Moo J. Cho, Ph.D.) 
Toll-like receptor 9 (TLR9) is an endosomal receptor expressed on immune cells.  
The receptor recognizes microbial DNA, which contains a higher frequency of unmethylated 
CpG sequences than host DNA.  Oligodeoxynucleotides containing such CpG motifs (CpG) 
are potent activators of TLR9, causing release of inflammatory cytokines and initiating both 
the innate and adaptive immune response.  CpG has been successfully used to treat solid 
tumors, but its use is limited by its unfavorable pharmacokinetics.  In preclinical studies, 
CpG was effective only when injected peritumorally; i.e., ineffective when administered 
systemically.  In an attempt to overcome this limitation, CpG was derivatized with a 
maleimide moiety to allow a chemical reaction with free thiols.  The derivative is referred to 
as CpG-mal throughout this dissertation.  
Albumin, the most abundant serum protein, contains one free thiol, Cys34, which 
comprises greater than 80% of the serum thiol content.  Consequently, upon intravenous 
injection, the CpG-mal will react with circulating albumin to form a 1:1 conjugate in a 
predictable manner.  Serum pharmacokinetics and biodistribution of phosphodiester CpG-
mal was investigated in tumor-bearing mice using a PET/CT imaging procedure. For this 
series of studies, a novel tyrosine-containing crosslinker was synthesized to facilitate 
radioiodination of the CpG with 
124
I in high yields.  Imaging studies revealed the reaction 
iii 
between the CpG-mal and albumin was fast enough to outcompete the high renal clearance of 
CpG, with the reaction complete within minutes.  The new CpG-albumin conjugate displayed 
a similar distribution pattern and plasma half-life as albumin; half-life was increased 70-fold 
and tumor accumulation was increased 30-fold over control CpG.   
In vitro plasma stability studies showed that albumin conjugation lead to a 1.5-fold 
reduction in the rate of enzymatic degradation of phosphodiester CpG.  An in vitro 
macrophage activation assay indicated that phosphodiester CpG-albumin conjugates were 
weak agonists of TLR9.  However, phosphorothioate CpG-albumin adducts were able to 
interact with TLR9 to initiate cytokine release from J774 macrophage cells, although this 
activity was reduced compared to control phosphorothioate CpG.  The activation was 
independent of crosslinker length, and introducing a reducible disulfide crosslinkage did not 
enhance the activity.  Pharmacokinetics and biodistribution of phosphorothioate CpG were 
measured using [
3
H]-labeled CpG.  The [
3
H]-CpG-mal had a longer plasma half-life than 
control CpG, however, the liver accumulation was significantly increased.  This liver uptake 
led to a less striking increase in tumor accumulation of CpG-mal than control CpG.   
In vivo tumor growth inhibition studies using a CT26 colon carcinoma model showed 
both the CpG-mal and control CpG were equally efficacious and caused complete tumor 
regression in 6/10 mice.  On the other hand, in the 4T1 model no tumor regression was 
observed presumably due to lack of tumor-associated antigens from the 4T1 cells.    
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 CHAPTER I: INTRODUCTION  
 
 
For every minute of 2013, it is predicted that one United States citizen will succumb 
to cancer.(Siegel, Naishadham et al., 2013)  The total direct and indirect economic impact of 
cancer-related healthcare in the United States for 2008 totaled $200 billion and will 
undoubtedly rise in the future.(Society, 2013)  Society needs better treatments for cancer, 
especially for younger patients.  Ideally, these treatments should be as cost effective as 
possible.  One potential way to reduce the cost of therapy and increase the effectiveness is to 
utilize existing natural defense mechanisms to our advantage. 
1.1 Cancer and Immunotherapy  
Current medical understanding of the pathophysiology of cancer suggests we are 
constantly under assault from cancer causing agents, be they ultraviolent rays from the sun, 
chemical carcinogens, radiation exposure, reactive oxygen species, or viral and bacterial 
infections.  Any of these agents can cause the genetic mutations that transform normal cells 
into cancer cells.  However, as these mutations occur, the human body is not constantly 
developing clinical tumors.  This implicates the existence of a controlling mechanism.  The 
cancer-controlling mechanism largely consists of two components: an intracellular and an 
extracellular mechanism.   
Cell growth is normally regulated tightly by many tumor suppressor genes and 
contact inhibition; furthermore, significant aberrant mutations lead to apoptosis.(Norbury and 
2 
Hickson, 2001)  The majority of transformed cells are thought to be repaired or eliminated by 
these intracellular mechanisms.  Some cells can accumulate mutations in these controlling 
genes and are rendered neoplastic. 
The extracellular phase is known as immunosurveillance and, more recently, 
immunoediting(Dunn, Old et al., 2004); the immune system is able to differentiate and 
destroy these abnormal cells before they develop into a tumor.  A number of experimental 
studies using genetically-engineered knockout mice with incomplete immune systems have 
an increase in tumor incidence. (Shankaran, Ikeda et al., 2001; Enzler, Gillessen et al., 2003; 
Street, Hayakawa et al., 2004)  Additionally, it is known that humans with 
immunodeficiencies have a greater chance of developing tumors.(Rabkin, Biggar et al., 1991; 
Grulich, van Leeuwen et al., 2007)  In some instances, abnormal cells are able to escape this 
control mechanism and their unchecked growth leads to cancer pathology.  The exact nature 
of how some cells escape the immunoediting mechanism is not currently well understood. 
One school of thought involves a selective proliferation of non-immunogenic cells lacking 
specific tumor antigens.  The consensus view of tumor immunobiology is that the lack of 
immune response is not merely due to an absence of immune cells in the vicinity of the 
tumor.  In fact, most tumors contain large amounts of immune cells.(Lin and Pollard, 2004)  
Rather, the issue appears to be that the cells have been anergized and no longer function as 
active immune cells.  They have been regulated by a sub population of T cells commonly 
known as Treg and other immunosurpessive cells that tell them that the tumor is not a 
threat.(Wolf, Wolf et al., 2003)   
There is a growing interest in using the immune system to detect and cure cancer, but 
the concept is not new.  Some of the earliest clinical uses of immunotherapy were performed 
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in the late 1890s by Dr. William Coley, who recognized that patients who suffered from 
bacterial infections showed a regression in tumor size.  He hypothesized that bacteria was the 
cause of tumors, and could be treated by injection of bacterial extracts.  His extracts 
contained two strains of bacteria and were injected in or around the tumor.  As a result, the 
patients would become febrile and develop flu-like symptoms.  In cases that responded 
positively, the tumors would quickly undergo liquefactive necrosis and begin to dissipate.  
Repeated injections over the span of multiple months provided complete remission for his 
patients who initially had a positive response.  In patients that did not respond to the initial 
treatment, subsequent treatments were also ineffective, and these patients were given 
different therapies.  
Cancer vaccines are another type of heavily investigated- and thus heavily invested-  
immunotherapy.  This approach appears flawed because, by their very nature, cancers are 
heterogeneous and thus do not express the same antigens across the population.  The second 
issue with cancer vaccines is that clinicians have no way of knowing which antigens are 
present without a biopsy.  Additionally, tumors contain a heterogeneous population of cells.  
A single cancer vaccine can target a single antigen, but will not affect the tumors cells which 
do not express the specific antigen.  This would require a multi-vaccine approach, which 
further increases cost and feasibility issues.  Finally, from a philosophical standpoint, it is 
questionable whether researchers can select an appropriate set of antigens in vitro against 
tumors better than the patient’s own immune system in vivo.  
In spite of these conceptual flaws, from a cost-benefit perspective, immunotherapies 
are attractive mainly because they have the ability to exert an effect after the treatment has 
cleared the body.  This should translate to reduced treatment frequency and associated costs.   
4 
1.2 Biological Response Modifiers 
Humans have evolved in intimate contact with bacteria. Our immune systems have 
thus developed methods to detect and limit the threat bacteria pose to our survival.  A 
consequence of this natural progression is a system to detect the conserved components of 
bacteria that renders virtually any type of bacteria to be identifiable by the immune system.  
These conserved components are called pathogen-associated molecular patterns, or PAMPs.  
They include components from gram negative cell walls such as lipopolysaccharides (LPS), 
DNA and RNA, also flagella and other membrane-associated proteins.(Kawai and Akira, 
2010)  Some of the receptors that are responsible for detecting these are the Toll-like receptor 
(TLR) family.  When these PAMPs are detected by a TLR, the immune system becomes 
activated and primed for further activity.   
Bacterial DNA serves as a PAMP because it expresses higher levels of unmethylated 
cytidine-phosphate-guanosine (CpG) dinucleotide sequences.  In higher animals such as 
mammals, CpG sequences occur at a quarter of the frequency.(Bird, 1986)  The CpG regions 
are usually flanked by residues that potentiate the immune response,(Krieg, Wu et al., 1998) 
and most importantly the cytosine is highly methylated at the 5 position, which abolishes the 
immune-stimulating activity.(Krieg, Yi et al., 1995)  Due to these differences in 
unmethylated CpG expression, our immune system has a way to discriminate between our 
own self DNA and foreign bacterial DNA.  Mammalian mitochondrial DNA also contains 
high amounts of unmethylated CpG DNA. Thus, when released during blunt tissue trauma, it 
can activate the immune system independently of exogenous bacteria.(Zhang, Itagaki et al., 
2010)   
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Unmethylated CpG is recognized by toll-like receptor 9 (TLR9).  It is an intracellular 
membrane receptor expressed almost exclusively on immune cells.  TLR9 is thought to exist 
as a homodimer, and the majority is found in the endoplasmic reticulum.(Latz, Verma et al., 
2007)  When cells are exposed to CpG, TLR9 is localized to the endosomal membranes by a 
currently unknown mechanism,(Latz, Schoenemeyer et al., 2004) whereby proteolytic 
cleavage coverts the TLR9 into its active form.(Park, Brinkmann et al., 2008)  Upon CpG 
binding, the active form undergoes a conformational change and transmembrane binding of 
MyD88 occurs.(Latz, Verma et al., 2007)  MyD88 signaling eventually leads to activation of 
NF-κB and release of inflammatory cytokines.  These cytokines are able to initiate an innate 
immune response by activating macrophages and natural killer (NK) cells and also an 
adaptive response by dendritic cell activation of CD8+ T cells and activation of B cells 
(Figure 1.1).(Krieg, 2003) 
Biological response modifiers (BRMs) are attractive drug candidates for cancer 
therapy because they are able to overcome some of the issues associated with tumor 
vaccines.  Since BRM are immune adjuvants, they are capable of activating the immune 
system and potentiating targeting of tumor antigens by immune cells.  This also means that a 
poly-antigen response can be initiated, decreasing the chance that tumor cells will be able to 
escape by altering their antigen expression.  BRM can be used to either activate or potentiate 
the immune system.(Williams, Ha et al., 1999)  In addition to their use in cancer 
immunotherapy, they can be also be used in various clinical pathologies such as allergies or 
autoimmune disorders.(Gupta and Agrawal, 2010)   
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1.3 CpG Oligodeoxynucleotides 
CpG oligodeoxynucleotides (ODN) are short 6-23 nucleotide DNA molecules that 
bind to TLR9 and can mimic the effects of bacterial DNA.(Krieg, Yi et al., 1995)  Random 
screening showed the immune response to CpG ODN was sensitive to sequences flanking the 
CpG: the optimal sequence found for mice was GACGTT, whereas for larger animals, 
including humans and primates, the optimal sequence was GTCGTT.(Rankin, Pontarollo et 
al., 2001)   
Our bodies are not accustomed to having DNA exist outside the cells and have 
mechanisms to remove this potential danger.  Extracellular nucleases can rapidly cleave 
DNA into nucleotides; 5’- or 3’-exonucleases cleave DNA at the terminal ends while 
endonucleases can cleave anywhere along the strand.  The majority of nucleases present 
extracellularly and in plasma are 3’-exonucleases and to a lesser extent endonucleases and 
5’-exonucleases.  ODN that have a natural phosphodiester (PO) backbone are rapidly 
metabolized by these nucleases and have poor pharmacokinetics (PK).  This instability limits 
their therapeutic potential.   
Several strategies have emerged to increase the resistance of ODN to 
nucleases.(Crooke, 1992)  The most common has been to replace one of the oxygens in the 
phosphate group with a sulfur atom; this modification is called phosphorothioate (PS).  The 
PS backbone prevents cleavage of the ODN by nucleases and the ODN remain intact to be 
therapeutically active.  However, this modification also alters the physicochemical properties 
of the ODN and increases the hydrophobicity.  PS ODN have extensive non-specific binding 
to cell surfaces and proteins; they are known to bind to serum proteins and weakly bind to 
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albumin with a kd ~ 50-300 µM.(Srinivasan, Tewary et al., 1995)  This binding is not very 
tight as evidenced by the rapid distribution of ODN when injected into mice.(Sands, Gorey-
Feret et al., 1994)  In the physiological setting, PS ODN have affinities to other targets which 
seem to be collectively greater than that of albumin.   
CpG monotherapy has been used in the preclinical setting to treat solid tumors.  The 
general consensus is that the CpG must be injected near the site of the tumor to elicit a 
response.(Heckelsmiller, Rall et al., 2002; Nierkens, den Brok et al., 2009)  If it is injected 
systemically, the response is not sufficient enough to have clinical effects.  This is no doubt a 
consequence of the poor PK of ODN.  When they are injected systemically, only a small 
percentage of the dose arrives at the tumor, whereas if the dose is injected near the tumor, a 
higher amount of the drug is in the tumor vicinity before it diffuses out.  This suggests 
delivery to the tumor is a limiting step in the therapeutic potential of systemically-injected 
ODN.   
Our lab has previously shown that IgG antibodies can be used as a carrier for CpG to 
increase its systemic effectiveness.(Palma and Cho, 2007)  CpG was derivatized with a 2,4-
Dintriophenol (DNP) hapten and were injected into mice that had been previously 
immunized against DNP and therefore expressed a high anti-DNP IgG titer in their 
circulation.  The anti-DNP IgG were able to form monomeric immune conjugates with the 
DNP-CpG and increase the plasma half-life and tumor accumulation.  Consequently, the 
DNP-CpG was considerably more efficacious than underivatized CpG in tumor suppression.   
While this approach showed promise, it has limitations.  The biggest issue is the 
amount of specific IgG carrier.  The effectiveness of the therapy is directly proportional to 
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the amount of IgG present.(Cheung and Cho, 2010)  The average concentration of IgG in 
normal adults is 12 mg/ml.  This corresponds to the total amount of IgG for all antigens, but 
only a small fraction of the IgG will be specific for a single antigen.  This could be overcome 
by creating an active immune response prior to CpG-hapten therapy, but that would require 
extra time and more procedures.  Because of these limitations, we decided to investigate the 
potential of using a different endogenous carrier for CpG ODN that would be abundant and 
accessible.  
1.4 Serum Albumin 
The most abundant protein in our blood is serum albumin.  It has a molecular weight 
of 67 kDa and bears a net -19 charge at physiological pH.  In humans, the plasma 
concentration is approximately 40 mg/ml and the interstitial concentration is approximately 
20 mg/ml.  This concentration difference gives rise to oncotic pressure which balances blood 
pressure and potentiates osmotic pressure.  Albumin has several other functions in the body: 
it acts as a carrier for fatty acids, bilirubin, and numerous other endogenous ligands.(Peters, 
1996)  It also provides binding sites for numerous insoluble therapeutic agents.  The amount 
of albumin in the average human is approximately 350 g, and its half-life in healthy 
individuals is estimated to be approximately 20 days.   
At normal homeostasis albumin is thought to exist at steady state, where the rate of 
production is equal to the rate of catabolism.  The only site of albumin synthesis that has 
been discovered is the liver.(Peters, 1996)  The sites of catabolism have not been exclusively 
established because of the widespread distribution of albumin, but it is thought the skin and 
muscle account for the majority of albumin catabolism.  In order to conserve energy by 
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preventing unwarranted catabolism, a recycling receptor, FcRn, is expressed on endothelial 
cells and other phagocytic cells.(Akilesh, Christianson et al., 2007)  FcRn has a higher 
affinity for albumin at low pH, such as that found in the endosome, and lower affinity at 
neutral pH.  This pH-dependent binding is related to protonation of His residues of 
FcRn.(Andersen, Dee Qian et al., 2006; Andersen and Sandlie, 2009)  This allows the 
albumin to be recovered from the endosome and recycled back to the surface of the cell, and 
is responsible for the longer half-life that albumin and IgG have compared to other serum 
proteins.(Chaudhury, Mehnaz et al., 2003)   
There are several other receptors involved in the transport of albumin.  Albondin, or 
gp60, is an endothelial surface protein that can transcytose albumin into the extravascular 
space.(Schnitzer and Oh, 1994)  Other scavenger receptors, gp30 and gp18, have a higher 
affinity for modified or degraded albumin and lead to degradation, primarily in the liver, 
rather than transcytosis.(Schnitzer, Sung et al., 1992)   
The half-life and distribution of albumin scales with species weight: in mice, the 
halflife is 1.2 d, rat 2.5 d, rabbits 5.7 d, dogs 8 d, and humans 20 d.(Allison, 1960)  Albumin 
plasma profiles, when introduced via bolus injection, exhibit biphasic behavior.  They are 
indicative of an initial distribution to tissues followed by a slower clearance phase.  In 
humans, this distribution phase takes approximately 3 days to complete and the concentration 
drops to approximately 40% of the initial value.(Peters, 1996)   
The endothelial cells that constitute continuous capillaries have gaps between them 
which allow plasma carrying nutrients to flow out of the arterial capillaries and into the 
interstitium according to Starlings equation.  Interestingly, these gaps are approximately 4 
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nm, which approximates the size of albumin and as a result, normal vasculature can restrict 
the transport of albumin out of the vessels via hydrodynamic sieving.(Rippe, Rosengren et 
al., 2002)  The restriction is not a complete barrier to albumin escape but is sufficient to 
generate and maintain an albumin concentration gradient across the vessel wall.  It is not 
clearly established if the intercellular leakage implied by Starlings equation is, in fact, the 
albondin-mediated transcytosis which has since been discovered.  
Albumin has 35 Cys residues; 34 of these are engaged in disulfides leaving one free 
thiol, Cys34.  Cys34, albeit located within a hydrophobic cleft of the albumin molecule, is 
accessible to the surrounding solvent and accounts for up to 85% of the total free thiol 
content of blood.(Kratz, Warnecke et al., 2002)  Approximately 25% of Cys34 exists as a 
disulfide with small molecular weight thiols such as cysteine or glutathione attached.  
Despite being located on a large molecule, Cys34 is quite reactive because its pKa~5-6 is 
much lower than the pKa~8 for most thiols. It thus exists as thiolate anion at physiological 
pH,(Kratz, Warnecke et al., 2002) much more nucleophilic than a neutral free thiol group.    
Since albumin contains only one Cys34, it can be utilized as a specific handle to 
reproducibly derivatize albumin to form a 1:1 conjugate.  Several of the most common thiol-
specific chemistries are maleimide, haloacetyl, and pyridyl disulfide.  Maleimide groups 
undergo Michael addition with thiols to create a stable thioether.  Haloacetyls, commonly 
iodoacetyl or bromoacetyl, undergo substitution reaction to form stable thioethers.  In 
contrast, pyridyl disulfides undergo substitution to form a disulfide bond that can be 
reversibly reduced.  Of these, the maleimide is probably the most frequently used and 
currently researched, partly because the reaction is fast and no side products are generated.   
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Several studies have investigated the potential of using albumin as a carrier by 
modifying drugs with maleimide groups.(Elsadek and Kratz, 2012)  When the maleimide-
containing drugs are injected into animals they react covalently with Cys34 within 
minutes.(Kratz, Warnecke et al., 2002)  Due to this fast rate, it has been possible to inject 
maleimide-modified drugs and have them react with circulating albumin without appreciable 
loss.  While a 1:1 conjugate may seem like a poor loading capacity, it avoids the 
polyvalenancy which is known provoke an immune response and generate antibodies.(Singh, 
Kaur et al., 2004)  This may be even more important when using an immune-activating drug.  
Additionally, the more that albumin is modified, the more it is recognized as non-native and 
is subject to rapid clearance.(Stehle, Sinn et al., 1997)   
1.5 Albumin and Cancer 
Cancer cells are constantly dividing and thus require a high amount of nutrients to 
sustain their growth.  The need for sustenance requires the formation of new blood vessels, 
which leads to a high rate of angiogenesis.(Folkman, 1990)  Histological examinations 
suggest that the blood vessels surrounding tumors are different than normal vessels- having 
unusually large gaps between adjacent endothelial cells.(Hashizume, Baluk et al., 2000)  
Indeed, the scientific rationale of many nanoparticle drug therapies is exploiting this 
difference.(Jain and Stylianopoulos, 2010)  In order to clear out an area for new growth of 
tumor cells and neovascularization, tumors release various enzymes to degrade the adjacent 
extracellular matrix.  All of these biochemical phenomena induce an increase in permeability 
for macromolecules, including albumin, at the tumor vicinity.(Matsumura and Maeda, 1986; 
Yuan, Dellian et al., 1995)  Many cancer patients develop cachexia, a state of severe 
malnourishment, in part due to the tumor consuming a large amount of serum proteins and 
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nutrients to sustain its growth.(Stehle, Sinn et al., 1997)  This leads to a loss of body weight 
and low concentration of serum proteins.   
1.6 Proposed Studies 
Collectively, those facts and findings introduced above indicate that serum albumin 
could be used as a carrier of CpG ODN.  The proposed sequence of events that may happen 
in order to lead to a response can be described as follows: (i) upon intravenous injection, the 
majority of maleimide-modified CpG ODN will covalently bind to albumin thereby limiting 
their rapid clearance and distribution; (ii) the CpG-albumin conjugate will behave similarly 
to albumin and will have increased circulation half-life; (iii) the CpG-albumin will 
extravasate from the tumor endothelium near the tumor periphery to a higher extent due to 
local increased permeability; (iv) the CpG-albumin will be taken up by highly phagocytic 
cells, such as macrophages and dendritic cells, in the tumor vicinity; (v) CpG-albumin will 
bind to TLR9 and cause upregulation of cytokine release, NK cell activation, and silencing of 
immunosuppressive Treg cells; (vi) antigen-presenting cells (APCs) will sample tumor 
antigen and become activated, (vii) APCs will travel to lymph nodes to initiate clonal 
expansion of CD8+ T cells; (viii) CD8+ T cells will infiltrate the tumor and begin to destroy 
the tumor cells; and (ix) any distant metastases can be identified by the lasting immune 
response.  This scenario appears to be wholly consistent with the scientific knowledge well 
established thus far and represents the scope of this dissertation.   
Based on the aforementioned timeline several specific hypothesis can be stated and 
experimentally tested.  First, albumin conjugation of maleimide-CpG will increase the blood 
half live compared to unconjugated CpG.  Second, tumor exposure of maleimide-CpG will 
13 
be greater than unconjugated CpG.  Lastly, the therapeutic efficacy of maleimide-CpG will 
be increased compared to unconjugated CpG.  Experiments contained within this dissertation 
have been designed to test these stated hypotheses.   
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Figure 1.1.  The cellular mechanisms of immune activation by CpG ODN.  Image from Krieg, A.M. (2003) Nat 
Med, 9(7), 831-5. 
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 CHAPTER II: SYNTHESIS AND APPLICATION OF A 
HETEROTRIFUNCTIONAL CROSSLINKER FOR 
124
I-BASED PET 
IMAGING 
 
2.1 Overview 
An efficient method for radioiodinating drug-carrier conjugates where the site of 
iodination is contained within the crosslinker has been developed.  A heterotrifunctional 
crosslinker was synthesized with terminal maleimide and N-hydroxysuccinimide ester groups 
for conjugation to cargo and a centrally incorporated Tyr residue to allow facile labeling with 
124
I.  The crosslinker was applied to amino-modified oligodeoxynucleotides (ODN) in order 
to measure in vivo conjugation to Cys34 of circulating serum albumin.  It was found the in 
situ reaction was complete within minutes and proceeded quickly enough to dramatically 
alter the clearance and distribution of the ODN.  This labeling strategy could be used as a 
way to introduce any isotope of radioiodine to various drug-carrier combinations bearing the 
requisite functional groups.   
2.2 Introduction 
The ability to non-invasively measure the pharmacokinetics and biodistribution 
(PK/BD) of experimental therapeutics is a promising tool for the pharmaceutical scientist for 
a number of reasons.  Primarily, it enables longitudinal studies involving small animals 
where multiple blood/organ samplings are not experimentally feasible.(Rygh, Qin et al., 
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2011)  Additionally, since each animal can provide information at multiple time points, there 
is a net reduction in the total number of experimental animals needed to obtain an equivalent 
amount of information.  Finally, non-invasive imaging can be translated to a clinical setting.  
However, current imaging systems require a radioisotope as a label for detection.  
Incorporation of the desired label into the therapeutic may not be trivial, as often there is not 
an accessible labeling functionality.   
Considerable research is being performed using macromolecular carriers and 
nanoparticles to enhance the therapeutic potential of drugs, particularly for targeting drugs to 
solid tumors.(Bae and Park, 2011)  In many cases this involves crosslinking drug molecules 
to larger carrier molecules.  In this study, a labeling moiety is incorporated into the 
crosslinker itself, rendering radiolabeling of the conjugate independent of the drug or carrier.  
The purpose of these experiments was to investigate the potential of using serum albumin as 
carrier of ODN.  Other groups have shown that modifying therapeutics with a maleimide 
functional group allows them to covalently react with the Cys34 of circulating 
albumin.(Elsadek and Kratz, 2012)  This approach has been extensively applied to small 
molecule anticancer drugs(Chung and Kratz, 2006; Kratz, 2007) and various peptides(Leger, 
Thibaudeau et al., 2004; Thibaudeau, Leger et al., 2005; Xie, Yao et al., 2010).  The present 
work was designed to test whether this approach would also work for ODN and to 
specifically address whether the in situ reaction was fast enough to prevent the ODN from 
rapid distribution and excretion.(Lau, Graham et al., 2012)   
Positron emission tomography (PET) was chosen as the method to measure the 
PK/BD of modified ODN due to its resolution and quantification.  Normally, the preferred 
isotope for PET imaging is 
18
F (t1/2 = 110 min; β
+
 = 98%) but its short radiological t1/2 is not 
22 
applicable for measuring PK/BD at longer biological t1/2.  Iodine has several radioactive 
isotopes and the 
124
I isotope (t1/2 = 4.2 d; β
+ 
= 22%) can be used for PET imaging.  In spite of 
some limitations(Pentlow, Graham et al., 1996), 
124
I is successfully quantified.   
2.3 Experimental Procedures 
All chemicals, except where noted, were purchased from EMD Sciences or Sigma 
Aldrich and were ACS reagent grade or higher.   
2.3.1 Crosslinker Synthesis  (Scheme 2.1) 
1.  Mal-Tyr(tBu)-OtBu 
To a 25-mL round bottom flask was added 115 mg (0.54 mmol) of N-ε-
maleimidocaproic acid, 120 mg (0.62 mmol) of N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC·HCl), 75 mg (0.65 mmol) of N-hydroxysuccinimide 
(NHS), and 3 mL of dichloromethane (DCM).  After 15 min 200 mg (0.61 mmol) of H-
Tyr(tBu)-OtBu·HCl was added in 2 mL of DCM followed by 400 µL (2.9 mmol) of 
triethylamine.  After 4 h at 25°C the reaction mixture was evaporated and the residue was 
dissolved in 15 mL of ethyl acetate and extracted twice with 10 mL of 1N HCl and 10 mL of 
saturated brine.  The organic layer was dried over MgSO4 and dried in vacuo.  The residue 
was purified on silica gel using 1:1 ethyl acetate:petroleum ether to give 160 mg (60%) of a 
slight yellow oil.  1H NMR (400 MHz, CD3OD): δ 1.22 (m, 2H, –CH2CH2CH2–), 1.30 (s, 
9H, –OC(CH3)3), 1.38 (s, 9H, –OC(CH3)3), 1.5-1.6 (m, 4H, –CH2CH2CH2–), 2.18 (t, 2H, –
CH2C=O), 2.9-3.05 (m, 2H, CHCH2–), 3.44 (t, 2H, NCH2–), 4.56 (t, 1H, CHCH2–), 6.79 (s, 
2H, –CH=CH–), 6.9 (d, 2H, Ar–H,m), 7.1 (d, 2H, Ar–H,o).  13C NMR (100 MHz, CD3OD): 
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δ 174.4, 171.2, 154.2, 134.9, 134.2, 133.5, 132.2, 130.2, 129.3, 124.7, 124.2, 123.3, 37.2, 
35.3, 28.1, 27.2, 27.1, 26.1, 25.2.  
2.  Mal-Tyr 
To a 25-mL round bottom flask was added 650 mg of 1 and 8 mL of 50% 
trifluoroacetic acid in DCM.  After 10 h at 25°C, the solvent was evaporated under a stream 
of N2 and the product was recrystallized from acetone/DCM to give 425 mg (86%) of slight 
yellow crystals.  mp: 161-163°C.  1H NMR (400 MHz, (CD3)2CO): δ 1.25 (m, 2H, –
CH2CH2CH2–), 1.5-1.6 (m, 4H, –CH2CH2CH2–), 2.2 (t, 2H, –CH2C=O), 2.9-3.1 (m, 2H, 
CHCH2–), 3.44 (t, 2H, NCH2–), 4.7 (q, 1H, CHCH2–), 6.7 (d, 2H, Ar–H,m), 6.81 (s, 2H, –
CH=CH–), 7.08 (d, 2H, Ar–H,o), 7.32 (d, 1H, CONH–).  13C NMR (100 MHz, CD3OD): δ 
174.6, 173.8, 171.4, 156.1, 134.8, 134.0, 133.4, 130.4, 129.6, 127.9, 115.6, 115.2, 114.8, 
114.4, 37.2, 35.3, 28.0, 25.9, 25.1.  ESI-MS (neg, MeOH): m/z 373.1 [M – H]- 
3.  Mal-Tyr-TEG-COOH 
To a 25-mL round bottom flask was added 400 mg (1.1 mmol) of 2, 250 mg (2.2 
mmol) of NHS, and 5 mL of freshly distilled tetrahydrofuran (THF).  The reaction mixture 
was placed in an ice bath and 220 mg (1.1 mmol) of N,N’-Dicyclohexylcarbodiimide was 
added in 5 mL THF.  After 10 h the reaction mixture was filtered and dried in vacuo.  The 
residue was dissolved in 5 mL DCM, placed in an ice bath, and 350 mg (1.3 mmol) of 
carboxy-PEG4-amine was added followed by 250 µL (1.4 mmol) of N,N-
Diisopropylethylamine.  After 1 h the reaction mixture was diluted with 20 mL DCM and 
washed twice with 20 mL of 1N HCl and 20 mL of saturated brine.  The DCM layer was 
dried over MgSO4 and dried in vacuo.  The residue was purified on silica gel using 1% acetic 
24 
acid in 1:9 methanol:DCM to give 465 mg (70%) of a yellow oil.  1H NMR (400 MHz, 
CDCl3): δ 1.2 (m, 2H, –CH2CH2CH2–), 1.5-1.6 (m, 4H, –CH2CH2CH2–), 2.2 (t, 2H, –
CH2C=O), 2.6 (t, 2H, –CH2CH2CO–), 2.9 (m, 2H, CHCH2–), 3.2-3.7 (m, 18H, –
CH2CH2O–), 3.79 (t, 2H, NCH2–), 4.68 (q, 1H, CHCH2–), 6.71 (s, 2H, –CH=CH–), 6.76 (d, 
2H, Ar–H,m), 7.01 (d, 2H, Ar–H,o), 7.06 (d, 1H, –CONHCH–) 7.38 (t, 1H, –CONHCH2– ).  
13C NMR (100 MHz, CDCl3): δ 174.8, 173.5, 172.0, 171.1, 155.8, 134.4, 134.1, 130.6, 
130.2, 127.6, 115.8, 115.6, 70.5 70.1, 66.8, 37.8, 36.2, 35.4, 28.5, 26.4, 25.2.  ESI-MS (neg, 
MeOH): m/z 620.2 [M – H]- 
4.  Mal-Tyr-TEG-NHS 
To a 25-mL round bottom flask was added 200 mg (0.3 mmol) of 3, 115 mg (1 mmol) 
of NHS, 80 mg (0.4 mmol) of EDC·HCl and 7 mL of DCM.  The reaction was carried out at 
4°C for 10 h.  The reaction mixture was diluted with 20 mL of DCM and washed twice with 
20 mL 1N HCl, 20 mL of saturated bicarbonate, and 20 mL saturated brine.  The DCM layer 
was dried using MgSO4 and was concentrated in vacuo to give 150 mg (65%) of a slight 
yellow oil.  1H NMR (400 MHz, CDCl3): δ 1.2 (m, 2H, –CH2CH2CH2–), 1.5-1.6 (m, 4H, –
CH2CH2CH2–), 2.2 (t, 2H, –CH2C=O), 2.8-2.9 (m, 6H, C=OCH2CH2C=O, –CH2CH2CO–
), 2.9-3.0 (m, 2H, CHCH2–), 3.2-3.7 (m, 18H, –CH2CH2O–), 3.82 (t, 2H, NCH2–), 4.55 (q, 
1H, CHCH2–), 6.28 (t, 1H, –CONHCH2– ), 6.45 (d, 1H, –CONHCH–), 6.69 (s, 2H, –
CH=CH–), 6.76 (d, 2H, Ar–H,m), 7.04 (d, 2H, Ar–H,o), 7.45 (s, 1H, COH).  13C NMR (100 
MHz, CDCl3): δ 172.7, 171.1, 169.4, 167.0, 155.8, 134.4, 134.1, 130.7, 128.0, 116.0, 70.8, 
70.6, 70.3, 65.9, 37.8, 36.4, 32.2, 28.4, 26.4, 25.8, 25.2.   ESI-MS (pos, MeOH): m/z 741.5 
[M + Na]+ 
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2.3.2 ODN Chemistry 
The ODN used in all experiments was a 20mer purchased from either Integrated 
DNA Technologies (Coralville, IA) or from Girindus America, Inc. (Cincinnati, OH) with a 
phosphodiester backbone, unless specifically stated.  They were supplied as the Na
+
 salt 
form.  The sequence was TCCATGACGTTCCTGACGTT and contained a commercially 
available 3’-amino modification.   
HPLC Conditions 
All HPLC analysis and purification was performed using Shimadzu SCL-10A system 
controller with two Shimadzu LC-8A pumps connected to a Rainin Dynamax UV-C detector 
and a Shimadzu C-R6A Chromatopac recorder.  Solvent A was 5% acetonitrile in 10 mM 
triethylammonium acetate buffer; solvent B was 100% acetonitrile.  For analytical work an 
Agilent Zorbax 300SB-C18 4.6 x 150mm analytical column with 5 µm particle size and a 
total flow rate of 1.0 mL/min was used with the following gradient: t = 0-5 min, %B = 0; t = 
5-30 min, %B = 0-25; t = 30-33 min, %B = 25-100.  For purification work the same gradient 
protocol was used with an Agilent Zorbax 300SB-C18 9.4 x 250mm semi-preparative 
column and a total flow rate of 4 mL/min.  All detection was performed at λ = 260 nm.   
ODN-mal 
To a 3-dram glass vial containing 13 mg (2.1 µmol) of ODN-NH2 in 2 mL of 0.1M 
sodium phosphate buffer, pH = 7.4 was added 20 mg (28 µmol) of 4 in 850 µL of 
acetonitrile.  The reaction progress was judged complete after 1.5 h at 25°C by analytical 
HPLC.  The acetonitrile was evaporated under a stream of N2 and the reaction mixture was 
purified using semi-preparative HPLC.  The product peak was manually collected and 
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evaporated in vacuo after addition of excess 3 M sodium acetate to acidify the pH to 5.2.  
The ODN was then ethanol precipitated from 0.3M sodium acetate at -20°C to give 7 mg 
(56%) of ODN-mal as a Na
+
 salt.  ESI-MS (neg, H2O) 7194.4 [M], 7211.8 [M + NH4]. 
ODN-COOH 
To a microcentrifuge tube containing 900 µg of ODN-mal was added 200 µL of 50 
mM NaOH.  After 4 h at 37ºC the ODN was ethanol precipitated from 0.3 M sodium acetate 
to give 840 µg (93%) of ODN-COOH as a Na
+
 salt.   
Murine Mercaptalbumin 
Mouse serum albumin (MSA) Fraction V was purchased from MP Biomedicals 
(Solon, OH).  Reaction with Ellman’s reagent indicated that the free thiol content of this 
albumin ranged from 0.2-0.3 mol of thiol per mol of MSA.(Janatova, Fuller et al., 1968)  
Mercaptalbumin was generated by the addition of 3 molar equivalents of DL-Dithiothreitol 
and incubation for 5 min at 25°C.(Funk, Li et al., 2010)  The unquenched reaction was 
directly applied to a Sephadex® G-25 size exclusion column equilibrated with phosphate 
buffered saline (PBS).  The unretained fractions containing MSA, as measured by UV, were 
pooled and Ellman’s test indicated the thiol content was 0.9-1.0 mol of thiol per mol of 
MSA.  The MSA was further purified by mini-Q strong anion exchange spin columns 
(Pierce, Rockford, IL) and eluted with PBS to generate mercaptalbumin in a manner similar 
to methods previously reported.(Janatova, Fuller et al., 1968)   
ODN-MSA 
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Radiolabeled ODN-mal was added to 8 equivalents of mercaptalbumin in PBS for 2 h 
at 25°C.  The reaction mixture was loaded onto Q strong anion exchange spin columns and 
eluted with increasing stepwise NaCl gradient in 20 mM phosphate buffer, pH = 7.4.  
Unreacted MSA was eluted with 300 mM NaCl and the conjugate was eluted with 400 mM 
NaCl.  The buffer was exchanged to PBS by repetitive ultracentrifugation using 30 kDa 
molecular weight cut off (MWCO) filters.   
2.3.3 Pharmacokinetic Experiments 
Iodination of ODN and MSA 
The ODN were iodinated using pre-coated Iodogen® tubes (Pierce, Rockford, IL).  
Na
124
I was purchased from IBA Molecular (Richmond, VA).  The Na
124
I needed to be 
regenerated to in order obtain reliable yields.  The regeneration process consisted of 
calculated addition of stock solution containing 1 mg/mL of NaI and 1 mg/mL of NaIO3 in 1 
mM NaOH.(Verel, Visser et al., 2004)  The general procedure was as follows:  The ODN to 
be labeled was dissolved in 100 µL of 100 mM sodium phosphate buffer at pH 7.4.  To a pre-
rinsed iodination tube, added were Na
124
I and a calculated amount of regeneration stock 
containing 0.9 mol equivalent of total iodine relative to ODN.  After 1 min the ODN was 
added to the tube and the reaction was allowed to progress for 6 min with periodic gentle 
shaking.  The unquenched reaction was directly applied to a Sephadex
®
 G-25 size exclusion 
column equilibrated with PBS.  The fractions containing ODN, as measured by UV, were 
pooled and concentrated using ultracentrifugation with 3 kDa MWCO filters.  MSA was 
labeled using a similar procedure.   
Mice and Tumor Model 
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All animals were handled in accordance with an approved protocol by UNC 
Institutional Animal Care and Use Committee.  4T1 cells were purchased from ATCC 
(Manassas, VA) and grown according to ATCC recommendations.  Eight female Balb/c 
mice, 18-20 g, were orthotopically inoculated with 1 x 10
5
 4T1 cells in 50 µL PBS by 
subcutaneous injection into the mammary fad pad.  The mice were randomly divided into 
four groups and imaging experiments began 15 days after tumor inoculation.   
PET Image Acquisition 
One day prior and throughout the imaging experiments mice were supplied ad libitum 
drinking water supplemented with 0.1% KI to block thyroid uptake of labeled 
124
I.(Verel, 
Visser et al., 2004)  All animals were anesthetized using isoflurane and catheterized via tail 
vein.  For each scan, two mice were placed on a cardboard platform on the scanning bed of a 
GE VISTA eXplore scanner and secured with surgical tape.  A heart and breathing rate probe 
was used to monitor vitals while scanning.  The mice were first imaged with a CT scan and 
then were dynamically imaged with PET for 1 h.  The animals were injected with 0.2-0.3 
mCi of 
124
I labeled material corresponding to 100 µg of ODN in 100 µL of sterile 0.22 µm 
filtered PBS and the catheters were flushed with a minimal volume of normal saline.  The 
amount of activity remaining in the catheter and syringe was measured using a calibrated 
dose calorimeter (Capintec CRC
®
-25R, Ramsey, NJ) and subtracted from the initial amount 
to quantify the amount of injected activity.   
Image Processing 
The raw data was rebinned according to the following scheme: 0-10 minutes, 1-min 
intervals; 10-30 minutes, 2-min intervals; and 30-60 minutes, 3-minute intervals.  Images 
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were reconstructed using an attenuation correction, scatter correction, and 2D OSEM 
projection using the supplied manufacturer software (MMWKS Image Software, Laboratorio 
de Imagen HGUGM, Spain).  The images were then loaded into AMIDE for 
analysis.(Loening and Gambhir, 2003)  The images were aligned using fiducial markers 
placed below the scanning bed.  Three-dimensional regions of interest (ROI) were manually 
drawn around the heart and bladder using the CT images.  The amount of PET signal 
contained within a ROI was calculated and converted to percent of injected dose per mL 
(%ID/mL) using appropriate conversions to correct for time decay and a cylindrical phantom 
of known activity.   
2.4 Results  
2.4.1 Crosslinker Synthesis 
The crosslinker used throughout this investigation was synthesized using 
carbodiimide chemistry from the amino acid Tyr according to Scheme 2.1.  A maleimide 
group was first conjugated to the –NH2 terminus of di-t-butyl protected Tyr using EDC.  
After subsequent t-butyl deprotection, the –COOH terminus was converted to an NHS ester 
using DCC.  Conjugation of this intermediate to the ODN-NH2 was attempted but no reaction 
was observed.  The failure was attributed to low aqueous solubility and stearic hindrance.  
Subsequently, a tetra(ethylene glycol) spacer was added to the crosslinker, which 
successfully enabled conjugation to ODN-NH2.  The final crosslinker was synthesized in 
overall yield of 25% over 4 steps.   
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2.4.2 ODN Preparation and Iodination 
The crosslinker 4 was conjugated to ODN-NH2 using standard 
conditions.(Hermanson, 1996)  Non-thiol reactive control ODN-COOH was synthesized 
from ODN-mal by hydrolysis of the maleimide group under basic conditions.(El-Sagheer, 
Cheong et al., 2011)  The structures of the ODN are shown in Figure 2.2.  Thiol reactivity 
was monitored using a mercaptohexanol HPLC shift assay; ODN-mal underwent a reaction 
as evidenced by an increase in peak retention time, whereas ODN-COOH showed no change 
in peak retention time when treated with mercaptohexanol.   
Conjugation with the crosslinker enabled the ODN to be iodinated with 
124
I using 
commercially available pre-coated Iodogen
®
 tubes in yields ranging from 80-90%.  In a 
control experiment, ODN-NH2 was modified with a crosslinker which did not contain a Tyr 
residue.  These ODN were not iodinated with the same iodination protocol; yields <0.5%.  
This result suggests the labeling was specific to the Tyr and not due to non-specific labeling 
of the ODN bases which can occur at elevated temperatures and extended labeling 
times.(Piatyszek, Jarmolowski et al., 1988)   
2.4.3 Image Analysis 
PET/CT whole body images, Figure 2.3, show this difference in initial distribution of 
the different treatments.  MSA and MSA-ODN are restricted to the vasculature volume and 
show high heart signal, whereas the ODN-COOH is rapidly cleared and distributed showing 
low heart signal.  ODN-mal shows a combination of these two patterns.   
Time-dependent radioactivity curves of blood and urine were generated by integrating 
the total PET signal contained within an ROI outlining the heart and bladder (Figure 2.4).  
31 
The heart is classically assumed to be highly perfused with blood; therefore blood 
concentration was approximated by total heart concentration.(Bading, Horling et al., 2008)  
The concentrations were dose-normalized and expressed as %ID/mL.   
ODN typically have a PK profile that can be characterized by rapid elimination from 
the plasma(Sands, Gorey-Feret et al., 1994), which is similar to the profile of ODN-COOH in 
Figure 2.4.  On the other hand, ODN-mal shows a different plasma profile.  Initially there is 
a steep drop, similar to ODN-COOH, which then transitions to a much slower plasma 
clearance.  The transition appears to be complete after approximately 8 min.  To confirm 
Cys34 of albumin is the major reaction product, ODN-mal was preconjugated to MSA ex vivo 
prior to injection.  This curve did not display a rapid plasma clearance indicating there was 
no significant free ODN contamination.  However, there was a delayed disappearance from 
the plasma and into the bladder.  MSA was used as a control in order to determine if there 
was a difference between the ODN-MSA conjugates and native albumin.  Both the MSA and 
ODN-MSA appear to be restricted to vascular space and do not undergo a rapid distribution.   
2.5 Discussion 
The crosslinker synthesized for this study was specifically designed to accommodate 
the following three functionalities:  (i) a maleimide group for conjugation to -SH groups; (ii) 
an activated ester for conjugation to -NH2 groups; and (iii) a phenol group for 
124
I PET label 
incorporation.  Therefore, the tertiary nature of the Tyr was utilized as the scaffold for the 
crosslinker.  The crosslinker was conjugated to ODN-NH2 and enabled specific radiolabeling 
of the Tyr.  An attempt was made to iodinate ODN-mal with a phosphorothioate backbone; 
however, yields were substantially lower. The phosphorothioate groups appear to interfere 
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with the oxidation.(Xie, Liang et al., 2012)  This observation shows the crosslinker requires 
compatibility with the drug or carrier and cannot be used indiscriminately.  In this case, no 
attempt was made to iodinate the crosslinker prior to conjugation with the phosphorothioate 
ODN-NH2.   
The cutoff for kidney filtration is approximately 40 kDa and continuous capillary 
endothelial gaps are approximately 4 nm (Rippe, Rosengren et al., 2002), therefore, there is 
no a priori reason to suspect any difference in renal clearance and distribution between 
ODN-COOH and ODN-mal.  Immediately upon injection and prior to any thiol reaction, 
these two ODN should have similar disposition.  However, the ODN-mal is able to undergo 
thiol addition which has the potential to alter disposition.  The ODN-mal blood curve should 
follow the ODN-COOH curve at early timepoints and begin to transition to a new curve as 
the thiol addition reaction occurs.  The majority of free thiol content in the blood is due to 
Cys34 of albumin(Kratz, Warnecke et al., 2002), therefore, this new curve should behave 
similar to albumin.  The expected biphasic nature of the ODN-mal blood curve is clearly 
observed in Figure 2.4.   
It appears that albumin is indeed the major reaction product based on the similar 
dispositions of preconjugated ODN-MSA to that of ODN-mal.  Interestingly, there was a 
delayed clearance of ODN-MSA and we speculate this is may be due to an impurity in the 
formulation, most likely dimer/multimer aggregates being recognized by scavenger receptors 
and degraded.(Schnitzer and Bravo, 1993)  It does not appear that monomeric ODN-MSA 
adduct is overtly recognized by scavenger receptors because no delayed degradation was 
observed in the ODN-mal curve and the plasma t1/2 is similar to MSA.   
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The blood and urine were not directly analyzed for stability of the label or integrity of 
the conjugate.  In preliminary experiments where the mice were not given KI-supplemented 
drinking water to block thyroid uptake, the amount of thyroid uptake was greater for labeled 
MSA compared to the ODN-mal (data not shown).  Additionally, labeled MSA was excreted 
predominantly through the urine, whereas all other treatments containing the radiolabeled 
crosslinker were excreted in the both urine and feces.  Taken together these suggest the 
crosslinker iodination has greater in vivo dehalogenation stability than labeled protein 
tyrosines, which is in agreement with other reports of prosthetic iodinations.(Vaidyanathan 
and Zalutsky, 1990)   
In summary, we were able to develop a strategy of labeling drug-carrier conjugates by 
incorporating a Tyr residue into the crosslinker to allow direct iodination.  Placing the 
radiolabel within the crosslinker should not interfere with the drug or the carrier.  This should 
leave their biological functions intact.  Maleimide-modified ODN were able to covalently 
react with Cys34 of circulating albumin and the reaction was complete within minutes which 
was fast enough to outcompete the rapid plasma clearance of the ODN.  The conjugation to 
albumin has a dramatic effect on the PK/BD of ODN.  Regardless of the radioisotope of 
iodine employed, the crosslinker is a promising tool due to its modular nature and could be 
used to study a variety of different drug-carrier combinations in numerous experimental 
settings.   
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Scheme 2.1.  Synthetic scheme for the synthesis 
of the heterotrifunctional crosslinker used 
throughout this study. 
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Figure 2.2.  Chemical structures of the modified ODN 
synthesized for the study.  The site of 
124
I labeling is ortho 
to the tyrosine phenolic hydroxyl, both mono- and di- 
iodinated ODN were observed.   
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A      B 
C      D 
Figure 2.3.  Normalized whole body PET/CT images of 
biodistribution of the 
124
I radiolabeled treatments after 20 min post 
injection. Each panel shows a coronal slice through the heart of two 
mice that were simultaneously imaged.  Panel A: ODN-COOH, B: 
MSA, C: ODN-mal, D: ODN-MSA.  All images were normalized by 
scaling the maximum color threshold with average injected dose.   
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Figure 2.4.  Time activity curves for the blood and urine during 1 h post injection.  Rapid clearance from the 
blood and into the urine is observed for the control ODN-COOH.  Reduced blood clearance and urine excretion 
is observed for ODN-mal, ODN-MSA, and MSA.  Each point represents the average of 2 mice imaged 
simultaneously.   
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 CHAPTER III:  PHARMACOKINETICS/BIODISTRIBUTION AND 
PHARMACODYNAMICS OF MALEMIDE DERIVATIZED 
OLIGODEOXYNUCLEOTIDES WITH PHOSPHODIESTER BACKBONE IN 
TUMOR BEARING MICE 
 
 
3.1 Overview 
A 20-mer CpG oligodeoxynucleotide (ODN) with a phosphodiester backbone was 
derivatized with maleimide (CpG-mal) at 3’-end to promote their reaction with Cys34 of 
serum albumin.  In vitro plasma stability indicated albumin conjugation could partially 
protect the CpG from nuclease degradation.  Pharmacokinetics (PK) and biodistribution (BD) 
were measured by PET/CT imaging of [
124
I]-labeled CpG-mal.  Plasma and tumor exposure 
of CpG-mal was increased 70- and 30-fold, respectively, compared to control CpG.  In vivo 
efficacy was measured in an orthotopic 4T1 murine breast carcinoma model.  No difference 
was observed in tumor growth, post-resection survival, or number of lung metastasis for any 
treatments compared to negative control.  In vitro macrophage activation was assessed by IL-
6 and IL-12 production in J774 cells.  The lack of antitumor response is explained by the 
weak agonist properties of CpG with phosphodiester backbone.   
3.2 Introduction 
Cancer immunotherapy is a promising field of cancer research that has yet to live up 
to its potential.  Systemic CpG monotherapy as a cancer treatment is presumably limited by 
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the low uptake by dendritic cells and macrophages in the tumor vicinity due to the poor 
plasma PK and tumor accumulation of CpG.  A method of increasing the plasma halflife of 
systemically-administered CpG should allow more opportunity for the CpG to interact with 
the tumor tissue and increase the tumor exposure, thereby improving efficacy.(Palma and 
Cho, 2007)  Using serum albumin as a carrier of anticancer drugs is an attractive way to 
increase the plasma half-life and tumor exposure.(Elsadek and Kratz, 2012)  Derivatizing 
therapeutics with maleimide groups to allow them to covalently react with Cys34 of serum 
albumin.(Kratz, Warnecke et al., 2002)  Maleimide-modified ODN were able to covalently 
bind with circulating albumin within minutes which dramatically reduced the initial 
distribution of the ODN compared to control ODN which was otherwise rapidly cleared from 
the blood (Figure 2.4).  Importantly, the study showed that albumin could be accessed by 
CpG-mal quickly enough to outcompete the rapid clearance of free CpG-mal so that ex vivo 
albumin conjugation was unnecessary.   
The purpose of this study is to determine the PK and BD of CpG-mal and to test the 
efficacy in tumor-bearing mice.  A rationale for exploring CpG immunotherapies lies in the 
premise that they can lead to both an innate and an adaptive immune response that causes 
primary tumor regression, prevent tumor reoccurrence, and treat distant 
metastases.(Kawarada, Ganss et al., 2001; Kunikata, Sano et al., 2004)  Advances in surgery 
have led to a good prognosis for non-metastatic primary tumors; however, prognosis is 
considerably worse after the presence of metastases.  Therefore treatment of metastasis is of 
paramount clinical importance.   
The interaction between tissue stroma and cancer cells has an effect on the 
development of solid tumors.(Tlsty and Coussens, 2006; Ma, Dahiya et al., 2009)  The use of 
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xenograph models may not sufficiently replicate this delicate balance.  For these reasons we 
have chosen to use a most aggressive orthotopic breast cancer model that is capable of 
metastasis in order to test the efficacy of the CpG therapy.   
3.3 Experimental Procedures 
All chemicals, except where noted, were purchased from EMD Sciences or Sigma 
Aldrich and were ACS reagent grade or higher.   
3.3.1 CpG ODN Chemistry 
Unless specifically stated, the CpG used in all experiments were purchased from 
either Integrated DNA Technologies (Coralville, IA) or from Girindus America, Inc. 
(Cincinnati, OH) with a phosphodiester backbone.  They are supplied as the Na
+
 salt form.  
The CpG-NH2 sequence was CpG1826:  TCCATGACGTTCCTGACGTT and contained a 
commercially available 3’-amino modification; non-stimulatory GpC-NH2 sequence 
CpG1982:  TCCAGGACTTCTCTCAGGTT was also purchased with a commercially 
available 3’-amino modification.  Unmodified CpG1826 (CpG) was also purchased.   
HPLC Conditions 
All HPLC analysis and purification was performed using Shimadzu SCL-10A system 
controller with two Shimadzu LC-8A pumps connected to a Rainin Dynamax UV-C detector 
and a Shimadzu C-R6A Chromatopac recorder.  Solvent A was 5% acetonitrile in 10 mM 
triethylammonium acetate buffer; solvent B was 100% acetonitrile.  For analytical work an 
Agilent Zorbax 300SB-C18 4.6 x 150 mm analytical column with 5 µm particle size was 
used with a total flow rate of 1 mL/min using the following gradient: t = 0-5 min, %B = 0; t = 
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5-30 min, %B = 0-25; and t = 30-33 min, %B = 25-100.  For purification work the same 
gradient protocol was used but with an Agilent Zorbax 300SB-C18 9.4 x 250 mm semi-
preparative column and a total flow rate of 4 mL/min.  All detection was performed at λ = 
260 nm.   
CpG-mal 
To a microcentrifuge tube containing CpG-NH2 in 100 mM sodium phosphate buffer 
at pH = 7.4 was added 20 equivalents of N-(ε-Maeimidocaproyloxy)succinimide ester 
(EMCS) (Pierce, Rockford, IL) in acetonitrile.  After 90 min at 25°C the reaction was judged 
complete by analytical HPLC.  The mixture was concentrated under a stream of N2 and 
purified using semi-preparative HPLC.  The desired peak was manually collected and 
concentrated in vacuo after acidification to pH = 5.2 by the addition of excess 3M sodium 
acetate buffer.  The CpG-mal was ethanol precipitated from 0.3 M sodium acetate to give the 
Na
+
 salt; yields: 55-70%.  ESI-MS (neg, H2O) 6461.2 [M] 
CpG-COOH 
To a microcentrifuge tube containing CpG-mal was added 50 mM NaOH. After 2h at 
37°C the reaction was judged complete by analytical HPLC.  The CpG-COOH was ethanol 
precipitated from 0.3 M sodium acetate at -20°C to give the Na
+
 salt; yield: 97%.   
CpG-MSA Conjugation 
Mouse serum albumin (MSA) Fraction V was purchased from MP Biomedicals 
(Solon, OH).  Conjugation of CpG-mal to MSA was performed according to a previously 
described procedure in Section 2.3.2.  Briefly, MSA was reacted with 3 equivalents of DTT 
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for 5 min at 25°C to generate mercaptalbumin and separated on a Sephadex
®
 G-25 size 
exclusion column equilibrated with phosphate buffered saline (PBS).  The void fractions 
containing MSA were pooled and loaded onto a mini-Q strong anion exchange column 
(Pierce, Rockford, IL) and eluted with PBS.  The MSA was added in 8-fold excess to CpG-
mal in PBS.  After 2 h at 25°C the reaction mixture was loaded onto a mini-Q strong anion 
exchange column and eluted with increasing stepwise NaCl gradient in 20 mM sodium 
phosphate buffer pH = 7.4.  Unreacted MSA was eluted with 300 mM NaCl, CpG-albumin 
conjugate was eluted with 400 mM NaCl, and unreacted CpG-mal was eluted with 500 mM 
NaCl.  When phosphorothioate CpG-mal was used a stronger gradient was needed:  500 mM 
to elute unreacted MSA, 1 M NaCl to elute CpG-MSA, and 2 M NaCl to elute unreacted 
CpG-mal.  Buffer exchange to PBS was performed using 30 kDa molecular weight cut off 
(MWCO) ultracentrifugation (Millipore, Billerica, MA); yield: 50-70%. 
3.3.2 Pharmacokinetics and Biodistribution 
[
124
I] Radiolabeling  
Na
124
I was purchased from IBA Molecular (Richmond, VA) two days prior to 
iodination.  CpG-mal and CpG-COOH were radiolabeled with 
124
I according to a previous 
procedure described in Section 2.3.3.  Briefly, CpG-NH2 was conjugated to a maleimide 
crosslinker that contains a tyrosine residue and was radiolabelled with 
124
I using Iodogen
®
 
precoated tubes (Pierce, Rockford, IL).  The iodination protocol was as follows: CpG to be 
labeled was dissolved in 100 µL of 100 mM sodium phosphate buffer at pH 7.4.  To a pre-
rinsed iodination tube, added were Na
124
I and a calculated amount of 1 mg/mL of NaI and 1 
mg/mL of NaIO3 in 1 mM NaOH containing 0.9 mol equivalent of total iodine relative to 
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CpG.  After 1 min the CpG was added to the tube and the reaction was allowed to progress 
for 6 min at 25°C with periodic gentle shaking.  The unquenched reaction was directly 
applied to a Sephadex
®
 G-25 size exclusion column equilibrated with PBS.  The fractions 
containing CpG ODN, as measured by UV, were pooled and concentrated using 
ultracentrifugation with 3 kDa MWCO filters.  MSA was labeled using a similar procedure. 
Ex vivo conjugated CpG-MSA was prepared by using 
124
I labeled CpG-mal in the same 
manner as previously described.   
PET Image Acquisition 
One day prior and throughout the imaging experiments mice were supplied ad libitum 
drinking water supplemented with 0.1% KI to block thyroid uptake of labeled 
124
I.(Verel, 
Visser et al., 2004)  All animals were anesthetized using isoflurane and catheterized via tail 
vein.  For each scan, two mice were placed on a cardboard platform on the scanning bed of a 
GE VISTA eXplore scanner and secured with surgical tape.  A heart and breathing rate probe 
was used to monitor vitals while scanning.  The mice were first imaged with a CT scan and 
then were dynamically imaged with PET for 1 h and statically imaged at 4, 8, 16, 24, 36 hr 
for 5 minutes.  The animals were injected with 0.2-0.3 mCi of 
124
I labeled material 
corresponding to 100 µg of ODN in 100 µL of sterile 0.22 µm filtered PBS and the catheters 
were flushed with a minimal volume of normal saline.  The amount of activity remaining in 
the catheter and syringe was measured using a calibrated dose calorimeter (Capintec CRC
®
-
25R, Ramsey, NJ) and subtracted from the initial amount to quantify the amount of injected 
activity.   
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Immediately after the final image acquisition the mice were sacrificed by 
exsanguination by cardiac puncture under isoflurane anesthesia.  In order to remove any 
residual organ blood, each mouse was perfused for 4 min with fetal bovine serum containing 
100 IU/mL of heparin sodium using a peristaltic pump (Rainin Rabbit Plus, Woburn MA) at 
a flow rate of 1.5 mL/min by inserting and clamping a blunt needle into the left ventricle and 
cutting the vena cava.  The heart, lungs, liver, kidneys, spleen, and tumor were harvested, 
rinsed in PBS, blotted dry and inserted into preweighed microfuge vials.  The organs were 
stored at -20°C until the radioactivity was measured using a well gamma counter 
(PerkinElmer 2470 WIZARD
2
, Waltham, MA).   
Image Processing 
The raw data for the dynamic scan was rebinned according to the following scheme: 
0-10 minutes, 1-min intervals; 10-30 minutes, 2-min intervals; and 30-60 minutes, 3-minute 
intervals.  Images were reconstructed using an attenuation correction, scatter correction, and 
2D OSEM projection using the supplied manufacturer software (MMWKS Image Software, 
Laboratorio de Imagen HGUGM, Spain).  The images were then loaded into AMIDE for 
analysis.(Loening and Gambhir, 2003)  The images were aligned using fiducial markers 
placed below the scanning bed.  Three dimensional regions of interest (ROI) were manually 
drawn on the heart, tumor, lungs, liver, kidneys, and intestines using the CT images.  The 
amount of PET signal contained within a ROI was calculated and converted to percent of 
injected dose per mL (%ID/mL) using appropriate conversions to correct for time decay and 
a cylindrical phantom of known activity.  Non-compartmental and PK analysis were 
performed using MATLAB 2012b (The MathWorks, Inc., Natick, MA).   
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3.3.3 In Vitro Plasma Stability 
[
3
H] Radiolabeling 
CpG-NH2 was radiolabelled using the procedure of Graham et al.(Graham, Freier et 
al., 1993)  Briefly, 2 mg of CpG-NH2 was lyophilized from 200 µL of 0.1 M sodium 
phosphate buffer, pH = 7.8, containing 0.2 mM EDTA in microfuge tube.  To the dry powder 
was added 200 µL of T2O (5 Ci/g, Moravek Biochemicals; Brea, CA) and 8.3 µL of β-
mercaptoethanol.  After 6h at 90℃ the reaction mixture was subjected to repeated 
ultracentrifugation using 5kDa MWCO filters to remove the bulk of excess T2O.  
Exchangeable tritium was removed by several rounds of suspension in 1 mL H2O, incubation 
at 25°C for 1 h, and lyophilization.  The [
3
H]-CpG-NH2 (1.5 mg; 75% yield) was stored as a 
dry power at -20℃ until use.  Analytical HPLC indicated no degradation had occurred during 
the procedure and the [
3
H]-CpG-NH2 was processed with EMCS as above. 
Plasma Incubation 
Whole blood was collected from female Balb/c mice via cardiac puncture into 
heparinized tubes and was spun at 2,000 x g for 10 min at 25°C.  The supernatant was 
collected and filtered through 0.22 µm PVDF filters and stored at 4°C until use.  To a 
microfuge tube containing 200 µL of plasma at 37°C was added 25 µg of [
3
H]-CpG ODN in 
25 µL PBS.  At specified timepoints, a 25 µL aliquot was removed for size exclusion 
analysis.  For the [
3
H]-CpG-COOH sample an additional 5 µL aliquot was removed for gel 
electrophoresis and was added to 25 µL of urea gel loading buffer and stored at 4°C until use.  
A control experiment where 25 µg of CpG-mal was incubated in 225 µL of PBS at 37°C was 
also performed.   
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A 1 x 30 cm column was packed with Sephadex
®
 G-50 and equilibrated with PBS 
containing 5 mM EDTA.  The plasma aliquot was diluted with 25 µL of the column running 
buffer prior to column loading.  Fractions were collected using a Bio-Rad model 2110 
fraction collector set to 30 drops per fraction.  From each fraction 550 µL was removed and 
transferred to a 20 ml scintillation vial followed by the addition of 3 mL of Ultima Gold XR 
scintillation cocktail fluid.  The radioactivity in each vial was measured using a Packard Tri-
Carb 2900TR liquid scintillation analyzer and reported in DPM.   
The amount of radioactivity in each fraction was plotted versus fraction number.  
Since all fractions were of equal size, the area under the curve (AUC) was calculated by the 
summing the radioactivity over an empirically determined range of fractions corresponding 
to the column void and retention volumes.  The amount of degradation was calculated 
according to the following equation: 
                   
[           
    ]  [           
    ]
[        
    ]
 
The fraction degraded was plotted versus time and the data was fit using a least-squares 
linear regression algorithm.   
Gel electrophoresis 
Gel electrophoresis was performed using 15% Mini-PROTEAN® TBE-Urea Precast Gels 
(Bio-Rad, Hercules, CA) and run at 200V for 40 min.  The gels were stained with SYBR
®
 
Gold (Molecular Probes, Eugene, OR) and imaged using AlphaImager (Alpha Innotech, San 
Leandro, CA) equipped with a SYBR photographic filter.   
4T1 Tumor Growth Study 
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Fifty female Balb/c mice, age 6-8 weeks, were orthotopically inoculated with 1 x 10
5
 
syngeneic 4T1 cells in 50 µL PBS into the mammary fat pad.  Once the tumors were 
established reached a diameter of 5 mm, as measured by calipers, the mice were randomly 
divided into groups of 8 and experimental treatments were initiated.  A total of five tail vein 
injections were given every other day consisting of 100 µg equivalents of CpG in 100 µL 
PBS.  All treatments were sterile filtered using 0.22 µm PVDF membrane filters prior to 
injection.  The experiment treatment arms were as follows: group A received 100 µg of CpG-
mal, group B received 100 µg of GpC-mal, group C received 100 µg CpG-COOH, group D 
received 100 µl of PBS, group E received 100 µg of CpG.  The tumors were allowed to grow 
to a maximum diameter of 12 mm at which point they were surgically resected and flash-
frozen in liquid N2.   The mice were allowed to continue to survive until either of the humane 
endpoints of 20% loss of total body weight loss or body condition score ≤ 2 were reached.  
The mice were sacrificed by cervical dislocation after CO2 asphyxiation and the lungs and 
livers were harvested in formalin.  Tumor volumes were calculated as V = ½ab
2
, where a is 
longest diameter and b is the length of the perpendicular diameter in mm.  Metastatic nodules 
in the lungs were counted by gross visual inspection of the organ.   
3.3.4 In Vitro Macrophage Activation 
J774 cells were obtained from the UNC Tissue Culture Facility, with provenance 
from ATTC (Manassas, VA), and were cultured with Dubelco modified essential media 
supplemented with 10% bovine calf serum in 5% CO2 atmosphere at 37°C.  The cells were 
grown in T150 flasks and harvested by scraping when 80% confluence was reached.  All 
experiments were performed with cells with a passage number less than twenty.  For 
experiments, the entire contents of a T-150 flask would be transferred to a 24 well plate (ca. 
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7 x 10
5
 cells/well by hemocytometer count) in 1 mL/well of media.  After 4 h, the media was 
removed, and replaced with 900 µL of fresh media and 100 µL of PBS containing the desired 
treatment.  All treatments were sterile filtered using 0.22 µm PVDF membrane filters prior to 
dilution and addition to the cells.  After 20 h, the media was removed and spun at 1000 x g 
for 5 min at 25°C.  The supernatant was carefully removed and assayed within 1 h or frozen 
on dry ice and stored at -20°C until ELISA analysis.   
IL-6 and IL-12 (p40) ELISA kits and appropriate buffer sets were purchased from BD 
Biosciences (San Jose, CA).  The assays were performed in accordance to manufacturer’s 
instructions.  When dilutions were necessary the cell culture supernatant was diluted with 
assay diluent.  The absorbance was read at 450 nm and was corrected with 570 nm 
subtraction using a Hidex Plate Chameleon™V (Turku, Finland) plate reader.  The 
concentration of cytokine was then back calculated using the appropriate standard curve and 
dilution factors.  The results were assayed in duplicate and are expressed as the average. 
3.4 Results 
3.4.1 In Vitro Plasma Stability 
The stability of radiolabeled [
3
H]-CpG-COOH and [
3
H]-CpG-mal in undiluted mouse 
plasma was measured at various time points by size exclusion chromatography and gel 
electrophoresis.  A plot of the fraction degraded versus time is shown in Figure 3.1 and the 
slope indicates the [
3
H]-CpG-COOH and [
3
H]-CpG-mal were degraded in murine plasma at a 
rate of 2.3 and 1.5 % per hr, respectively, compared to a rate of 0.15 % per hr in PBS for 
[
3
H]-CpG-mal.  Gel electrophoresis of the [
3
H]-CpG-COOH showed the majority of the 
material corresponds to intact [
3
H]-CpG-COOH with a slow appears of smaller sequences.   
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3.4.2 Plasma Pharmacokinetics 
There was a dramatic difference in the plasma concentration profile of the [
124
I]-CpG-
mal versus [
124
I]-CpG-COOH, which can be seen in Figure 3.2.  The [
124
I]-CpG-COOH 
rapidly falls below the limit of the detection within 7 h, whereas, the [
124
I]-CpG-mal has a 
higher concentration and longer half-life and never reaches background levels during the 
course of the experiment.  When the data are fit to a two-compartment model the half-lives 
for [
124
I]-CpG-COOH and [
124
I]-CpG-mal were 0.3 h and 10 hr respectively.  The half-life of 
precomplexed [
124
I]-CpG-MSA was 7 hr which is similar to [
124
I]-CpG-mal and half-life of 
[
124
I]-MSA was 13 hr, which was longer than both of the CpG-albumin conjugates.   
3.4.3 Biodistribution and Tumor Accumulation  
The tumor accumulation of the different CpG ODN is shown in Figure 3.3.  [
124
I]-
CpG-COOH reached a maximal tumor accumulation of ~2 %ID/mL approximately 30 min 
after injection and begins to quickly drop thereafter.  On the other hand, [
124
I]-CpG-mal 
reached a maximum of ~3 %ID/mL approximately 4 h after injection and slowly decreases 
which is similar to ex vivo complexed [
124
I]-CpG-MSA.  [
124
I]-MSA had a tumor 
accumulation of ~5%ID/mL approximately 4 h after injection.  The tumor exposure was 
increased 30 fold for [
124
I]-CpG-mal compared to [
124
I]-CpG-COOH.   
The [
124
I]-CpG-COOH is rapidly excreted by the kidneys into the urine and no other 
organs appear to accumulate the drug.  On the other hand, [
124
I]-CpG-mal, [
124
I]-CpG-MSA, 
and [
124
I]-MSA show widespread distribution to all organs.  Post-sacrifice organ distribution, 
Figure 3.4, showed the majority of 
124
I radiolabel to be contained within the blood and the 
tumor had the next highest concentration.  The predominate mode of clearance was by the 
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kidneys and also by elimination in the feces.  [
124
I]-MSA appeared to be exclusively 
eliminated by the kidneys.   
3.4.4 4T1 Tumor Growth Study 
There was no difference in initial tumor growth rate prior to surgical resection 
between any of the study groups.  All of the groups showed a steady increase in tumor 
volume during treatment and the tumors were resected one week after the first treatment.  
Due to the aggressive nature of the 4T1 cells infiltrating adjacent muscle and skin tissue, 
complete surgical resection without major surgical intervention was not possible, but a 
drastic reduction in primary tumor burden was achieved.  Skin ulcerations which were 
attributed to complications from the surgery were prevalent and necessitated euthanasia.  No 
difference in the survival time post-surgery was observed across the study groups, as shown 
in Figure 3.5.   
3.4.5 In Vitro Cytokine Release 
The purpose of the in vitro activation study was to test CpG-albumin conjugates are 
active to antigen presenting cells in the absence of any physiological barriers limiting access 
to these cells.  The murine macrophage cell line J774 was incubated with various 
concentrations of different CpG treatments and ELISA against IL-6 and IL-12 was performed 
on the cell supernatants to determine the extent of activation.  It can be seen from the results 
in Figure 3.6 that the activation was reduced for CpG-albumin compared to CpG.  It is also 
clear from the results that phosphodiester CpG are not able to activate the macrophages as 
well as the phosphorothioate CpG.   
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3.5 Discussion 
It is possible that albumin conjugation may affect the interaction between CpG ODN 
and enzymatic nucleases and serve to protect them from degradation.  The CpG-COOH and 
CpG-mal were both moderately stable when incubated with mouse plasma in vitro and the 
CpG-mal was approximately 1.5 times more stable.  Since the 3’-end was modified these 
CpG were not subject to rapid degradation by 3’-exonucleases that are prevalent and 
responsible for the majority of degradation in plasma.(Eder, DeVine et al., 1991)  Other 
studies indicated that in vitro stability does not correlate to in vivo stability due to higher 
levels of cellular endonucleases.(Kang, Boado et al., 1995)  In this study the 
124
I radiolabel is 
located on the crosslinker linking the CpG to albumin.  The measured 
124
I radioactivity gives 
no information whether the CpG is still intact.  Therefore the results represent the upper limit 
of how long the CpG could remain assuming that degradation of the CpG does not influence 
the disposition.   
The 30-fold increase in tumor accumulation of [
124
I]-ODN-mal compared to [
124
I]-
ODN-COOH is attributed to the increased plasma t1/2 and increased vascular permeability in 
the tumor vicinity.(Matsumura and Maeda, 1986)  The extended retention of [
124
I]-ODN-mal 
compared to [
124
I]-ODN-COOH by the tumor is consistent with impaired lymphatics and 
reduced diffusion of the macromolecular conjugate versus the smaller ODN (74 kDa vs 7 
kDa) in the tumor microenvironment.(Matsumura and Maeda, 1986)  Although, the tumor 
has higher accumulation, it never appreciably exceeded the plasma concentration in our 
study.   
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Albumin has historically been used as a predictor of plasma volume because it does 
not readily extravasate and its distribution upon injection is limited to the intravascular 
volume.  The initial signals for the blood concentration are lower than would be expected and 
this may be related to using the heart ROI as an approximation of the blood concentration.  
The total heart ROI signal is composed of both the blood and heart tissue signals.  Figure 3.4 
shows the concentration of 
124
I in the blood was consistently greater than heart tissue so the 
majority of the heart signal comes from the blood.  This should lead to two signal 
distribtutions, a higher one for the blood volume and a lower one for the heart tissue.  
Interestingly, a histogram of the ROI signal did not reveal these two distinction signal 
distributions (data not shown).   
The lack of an efficacious response despite a difference in tumor accumulation 
prompted us to investigate whether albumin conjugation possibly interfered with TLR9 
signaling.  We found that phosphodiester CpG was not a very potent agonist of TLR9 which 
is in agreement with other studies and attribute this to nuclease instability.(Krieg, MATSON 
et al., 1996)  Replacing the CpG phosphodiester backbone with phosphorothioate 
significantly increases the activation of TLR9.  Modification of the 3’-end of CpG was not 
expected to alter the activation,(Kandimalla, Bhagat et al., 2002)  but we noticed a distinct 
difference which must related to the difference in nature of modification.  Conjugation of 
albumin further reduced the activation but did not totally abolish the activity.  It is concluded 
based on the results of the in vitro activation assay that the lack of in vivo efficacy was 
related to the PO CpG not being a potent TLR9 agonist.  
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Figure 3.1.  In vitro plasma stability of PO [
3
H]-CpG.   The difference in rate of degradation in plasma versus 
PBS buffer indicates enzymatic degradation.  Gel electrophoresis show the majority of remaining CpG is intact 
with the presence of some smaller sequences.  Equal size aliquots were loaded onto the gel, the reduction in 
staining intensity is due to fully degraded nucleotides running off gel.   
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Figure 3.2.  Blood concentration of 
124
I labeled CpG. CpG-COOH is rapidly cleared from the circulation 
whereas the other treatments exhibit prolonged blood retention.  The line represent the 2-compartment model fit 
parameters found in Table 3-1.  Each data point is the average of 2 animals imaged simultaneously.   
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Table 3-1.  Plasma and tumor exposure of the [
124
I]-labeled CpG.   
AUC were calculated by non-compartment analysis of the respective time activity curves.  Initial volume and 
compartmental rate constants are calculated from a 2-compartment model.   
 Plasma AUC  
(h %ID/ml) 
Tumor AUC 
(h %ID/ml) 
V1 
(mL) 
k10 
(h
-1
) 
k12 
(h
-1
) 
k21 
(h
-1
) 
[
124
I]-CpG-COOH 3 ± 1 7 ± 1 14.5 ± 1.4 2.4 ± 0.3 8.8 ± 1.0 1.1 ± 0.1 
[
124
I]-CpG-mal 196 ± 19 (69) 200 ± 32 (29) 8.5 ± 0.2 0.07 ± 0.02 0.5 ± 0.1 1.2 ± 0.2 
[
124
I]-CpG-MSA 185 ± 8 (65) 194 ± 99 (29) 8 ± 1.2 0.10 ± 0.01 0.6 ± 0.2 0.4 ± 0.1 
[
124
I]-MSA 305 ± 30 (107) 338 ± 103 (50) 6.8 ± 0.1 0.05 ± 0.01 0.43 ± 0.03 1.0 ± .09 
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Figure 3.3.  Tumor time activity curve showing tumor uptake of 
124
I labeled CpG. The CpG-COOH 
quickly rises and falls whereas all other treatments show increased accumulation and 
retention in the tumor.  Each data point is the average of 2 animals imaged simultaneously.   
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Figure 3.4.  Terminal biodistribution of 
124
I-labeled CpG measured by ex vivo gamma counting.  The time post 
injection the samples were extracted from the mice is shown in the legend.  For MSA and CpG-mal, N=4; for 
CpG-COOH and CpG-MSA, N =2.  Error bars represent the standard deviation of the measurements.  For CpG-
mal and MSA, one mouse had large lung uptake which was attributed to the formation of a clot, otherwise the 
blood had the highest concentration followed by the tumor for all albumin associated formulations.   
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Figure 3.5.  Survival after surgical resection of 4T1 primary tumor.  Red arrows represent treatment, the black 
arrow represents surgical resection.  In all treatment groups showed uniform lethality by 35 days after tumor 
inoculation and mice were euthanized prematurely due to skin ulcerations.  For all treatment groups N =8.   
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Figure 3.6.  In vitro IL-12 and IL-6 release from J444 cells. ELISA was performed on cell supernatant after 20 
h of incubation.   
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 CHAPTER IV:  PHARMACOKINETICS/BIODISTRIBUTION AND 
PHARMACODYNAMICS OF MALEMIDE-DERIVATIZED 
OLIGODEOXYNUCLEOTIDES WITH PHOSPHOROTHIOATE 
BACKBONE IN TUMOR-BEARING MICE 
 
 
4.1 Overview 
In an attempt to increase the efficacy of systemically injected CpG 
oligodeoxynucleotides with phosphorothioate backbone for cancer immunotherapy, they 
were modified with a maleimide group (CpG-mal) to promote in situ conjugation with Cys34 
of serum albumin.  The CpG-mal had a slower plasma distribution and longer plasma half-
life than control CpG (CpG-COOH) that cannot form such a conjugate.  The CpG-mal had 
lower kidney accumulation and increased spleen and liver accumulation compared to CpG-
COOH as well as increased tumor concentrations.  CpG-mal and CpG-COOH were both able 
to cause complete tumor regression in 60% of the mice bearing CT26 tumors but no tumor 
regression was observed for 4T1 tumors.  Increasing the length of the maleimide crosslinker 
or incorporating a reducible disulfide into the crosslinker did not significantly affect the in 
vitro activation of macrophages by CpG-albumin conjugates.   
4.2 Introduction 
CpG oligodeoxynucleotides (ODN) mimic bacterial DNA and act as toll-like receptor 
(TLR) 9 agonists to cause activation of the innate and adaptive immune response.(Krieg, Yi 
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et al., 1995)  CpG monotherapy is effective in murine cancer models upon peritumoral 
injection but never when administered systemically.(Heckelsmiller, Rall et al., 2002; 
Nierkens, den Brok et al., 2009)  The anti-tumor response appears to primarily involve CD8+ 
T cells, NK cells, and macrophages rather than CD4+ T cells.(Heckelsmiller, Rall et al., 
2002; Ballas, 2007; Buhtoiarov, Sondel et al., 2007)  The lack of efficacy for systemically-
injected CpG is presumably caused by low exposure due to the rapid plasma clearance of 
CpG.  In a previous study in our lab, it was shown that tumor exposure and efficacy of 
systemically injected CpG could be increased by making in situ monomeric IgG complexes 
of hapten-derivatized CpG injected into mice preimmunized against the hapten.(Palma and 
Cho, 2007)  While the results were quite promising, the clinical use may be limited due to 
low steady-state titers of specific IgG in humans.  In search of an alternative endogenous 
serum proteins that could be used as a carrier we have shown that maleimide-modified 
phosphodiester CpG were able to quickly react with serum albumin.  The in situ conjugation 
significantly altered the biodistribution increasing both the plasma half-life and tumor 
accumulation.  However, these CpG were not able to activate TLR9 to produce an immune 
response.  The present study was designed to test whether serum albumin could serve as a 
carrier of phosphorothioate CpG for cancer therapy in a similar fashion to immunoglobulins.   
In other studies where albumin has been used as a carrier of cytotoxic anticancer 
drugs the target has always been the cancer cells themselves.  This is in contrast to our study 
where the CpG-albumin target is the dendritic cells and macrophages within the tumor 
periphery. Accessing the tumor periphery is a much easier task due to the heterogeneous 
transport phenomena within tumor tissue.(Chauhan, Stylianopoulos et al., 2011)  
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Additionally, phagocytic cells are expected to accumulate more albumin than nonphagocytic 
cells.(Chang, 1969)   
4.3 Experimental Procedures 
CpG Chemistry 
The CpG1826 used in all experiments were purchased from Integrated DNA 
Technologies (Coralville, IA) with a phosphorothioate backbone as the Na
+
 salt.  The 
sequence was TCCATGACGTTCCTGACGTT and contained a commercially available 3’ 
amino modification.  CpG1826 with no modifications was also purchased. 
HPLC Conditions 
All HPLC analysis and purification was performed using Shimadzu SCL-10A system 
controller with two Shimadzu LC-8A pumps connected to a Rainin Dynamax UV-C detector 
and a Shimadzu C-R6A Chromatopac recorder.  Solvent A was 5% acetonitrile in 100 mM 
triethylammonium acetate buffer; solvent B was 100% acetonitrile.  For analytical work an 
Agilent Zorbax 300SB-C18 4.6 x 150mm analytical column with 5 µm particle size was used 
with a total flow rate of 1 ml/min using the following gradient: t = 0-5 min, %B = 0; t = 5-30 
min, %B = 0-25; t = 30-33 min, %B = 25-100.  For purification work, Solvent A was 5% 
acetonitrile in 10 mM triethylammonium acetate buffer and the same gradient protocol was 
used with an Agilent Zorbax 300SB-C18 9.4 x 250mm semi-preparative column and a total 
flow rate of 4 ml/min.  All detection was performed at λ = 260 nm.   
CpG-mal (Figure 4.1) 
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To a microcentrifuge tube containing CpG-NH2 in 100 mM sodium phosphate buffer 
pH = 7.4 was added 20 equivalents of EMCS in acetonitrile.  After 90 min at 25°C the 
reaction was judged complete by analytical HPLC.  The mixture was concentrated under a 
stream of N2 and purified using semi-preparative HPLC.  The desired peak was manually 
collected and concentrated in vacuo after acidification to pH = 5.2 by the addition of excess 3 
M sodium acetate buffer.  The CpG-mal was ethanol precipitated from 0.3 M sodium acetate 
to give the Na
+
 salt.   
CpG-COOH (Figure 4.1) 
To a microcentrifuge tube containing CpG-mal was added 50 mM NaOH solution.  
After 2 h at 37°C the reaction was judged complete by analytical HPLC.  The CpG-COOH 
was ethanol precipitated from 0.3 M sodium acetate at -20°C to give the Na
+
 salt.   
CpG-PEG24-mal 
To a microcentrifuge tube containing CpG-NH2 in 100 mM sodium phosphate buffer 
pH = 7.4 was added 20 equivalents of NHS-PEG24-mal in acetonitrile.  After 90 min at 25°C 
the reaction mixture separated by repeated ultracentrifugation using 5 kDa MWCO filters in 
0.3 M sodium acetate buffer pH = 5.2 to remove unreacted crosslinker.  The CpG-PEG24-
mal was ethanol precipitated from 0.3 M sodium acetate at -20°C to give the Na
+
 salt, yield: 
60%.   
CpG-SS-mal 
To a microcentrifuge tube containing CpG-NH2 in 100 mM sodium phosphate buffer 
pH = 7.4 was added 20 equivalents of S-SS-4FB (Solulink, San Diego, CA) in 
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dimethylformamide.  After 90 min at 25°C the reaction mixture separated by repeated 
ultracentrifugation using 5 kDa MWCO filters in 0.3 M sodium acetate pH = 5.2 buffer to 
remove unreacted crosslinker and 20 equivalents of N-β-Maleimidopropionic acid hydrazide 
(BMPH) was added.  After 30 min at 25°C the reaction mixture was ultracentrifuged to 
remove the unreacted crosslinker.  The CpG-SS-mal was ethanol precipitated from 0.3 M 
sodium acetate at -20°C to give the Na
+
 salt; yield: 55%.   
[
3
H] Radiolabeling of CpG 
CpG-NH2 was radiolabeled using the procedure of Graham, et al.(Graham, Freier et 
al., 1993) Briefly, 6 mg of CpG-NH2 was lyophilized from 200 µL of 0.1 M sodium 
phosphate buffer, pH = 7.8, containing 0.2 mM EDTA in microfuge tube.  To the dry powder 
was added 200 µL of T2O (5 Ci/g, Moravek Biochemicals; Brea, CA) and 8.3 µL of β-
mercaptoethanol.  After 6h at 90°C the reaction mixture was subjected to repeated 
ultracentrifugation using 5kDa MWCO filters to remove the bulk of excess T2O.  
Exchangeable tritium was removed by several rounds of suspension in 1 mL H2O, incubation 
at 25°C for 1 h, and lyophilization.  The [
3
H]-CpG-NH2 (4.1 mg; 68% yield) was stored as a 
dry power at -20℃ until use.  The specific activity (SA) was 3.1 x 104 DPM/µg.  Analytical 
HPLC indicated no degradation had occurred during the procedure and the [
3
H]-CpG-NH2 
was processed with EMCS as above. 
4.3.1 In Vitro Cytokine Release 
J774 cells were obtained from the UNC Tissue Culture Facility, with provenance 
from ATTC (Manassas, VA), and were cultured with Dubelco modified essential media 
supplemented with 10% bovine calf serum in 5% CO2 atmosphere at 37°C.  The cells were 
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grown in T150 flasks and harvested by scraping at 80% confluence.  All experiments were 
performed with cells with a passage number less than twenty.  For experiments, the entire 
contents of a T-150 flask would be transferred to a 24 well plate (ca. 7 x 10
5
 cells/well by 
hemocytometer count) in 1 mL/well of media.  After 4 h, the media was removed, and 
replaced with 900 µL of fresh media and 100 µL of PBS containing the desired treatment.  
All treatments were sterile filtered using 0.22 µm PVDF membrane filters prior to dilution 
and addition to the cells.  After 20 h, the media was removed and spun at 1000 x g for 5 min 
at 25°C.  The supernatant was carefully removed and assayed within 1 h or frozen on dry ice 
and stored at -20°C until ELISA analysis.   
IL-6 and IL-12 (p40) ELISA kits and appropriate buffer sets were purchased from BD 
Biosciences and 96-well plates were purchased from Nunc.  The assays were performed in 
accordance to manufacturer’s instructions with no modifications.  When dilutions were 
necessary the cell culture supernatant was diluted with assay diluent.  The absorbance was 
read at 450 nm and was corrected with 570 nm subtraction using a Mtech plate reader.  The 
concentration of cytokine was then back-calculated using the appropriate standard curve and 
dilution factors.  The results were assayed in duplicate and are expressed as the average ± 
standard deviation. 
CpG-albumin Conjugation 
CpG-albumin conjugates were prepared by a method previously reported in Section 
2.3.2.  Briefly, maleimide containing CpG was incubated with 8-fold molar excess murine 
mercaptalbumin for 2 h at 25°C in PBS.  The mixture was directly loaded onto Q strong 
anion spin columns (Pierce, Rockford, IL) and separated using a stepwise increasing NaCl 
71 
gradient in 20 mM sodium phosphate pH = 7.4 buffer.  Unreacted albumin was eluted using 
500 mM NaCl, CpG-albumin conjugate was eluted using 1 M NaCl, and unreacted CpG was 
eluted using 2 M NaCl.  Repetitive ultracentrifugation using 30 kDa MWCO filters was used 
to change the buffer to PBS and the conjugate was stored at 4°C not more than 48 h until use.   
Mice and Cell Lines 
All mice were handled in accordance with an approved protocol by UNC Institutional 
Animal Care and Use Committee.  Female Balb/c mice age, 8-10 weeks, were purchased 
from the National Cancer Institute (Bethesda, MD).  For tumor growth inhibition studies 
tumor size was measured by calipers three times per week and calculated as V = ½ab
2
, where 
a was the longest diameter and b was the length of the perpendicular diameter in mm.  Mice 
were allowed to survive until a maximum diameter of 2 cm was reached at which point they 
were sacrificed by cervical dislocation after CO2 euthanasia.  CT26 and 4T1 cell lines were 
purchased from ATCC (Manassas, VA) and grown according to the manufacturer’s 
recommendations.   
4.3.2 Pharmacokinetic and Biodistribution Study 
Fifty mice were inoculated subcutaneously in the right flank with 2.5 x 10
5
 CT26 
cells in 50 µL of Hank’s balanced buffer solution (HBSS).  After 10 days the mice were 
randomly divided into groups of 3 and were given tail vein injections of 100 µg of either 
[
3
H]CpG-mal (SA = 2.1 x 10
4
 DPM/µg) or [
3
H]CpG-COOH (SA = 2.1 x 10
4
 DPM/µg) in 
100 µL of PBS.  All treatments were sterile filtered using 0.22 µm PVDF filters prior to 
injection.  For [
3
H]-CpG-COOH, 3 mice were sacrificed by cardiac puncture at the following 
time points: 5, 10, 15, 30, 60, 120, 240 min after intraperitoneal injection of 100 µL of 100 
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mg/mL ketamine hydrochloride.  For [
3
H]-CpG-mal, mice were sacrificed in a similar 
manner at 10 min, 1, 4, 8, 15, 24, 42 hr.  Whole blood was collected into tubes containing 
EDTA and the heart, liver, spleen, kidneys, lungs, tumor and injection site were rinsed with 
PBS, blotted dry, and weighed in scintillation vials.  Whole organs were processed for 
radioactivity analysis except for the liver, which was cut into 100 mg pieces.  Whole blood 
was processed in triplicate 100 µL fractions.  To each tissue sample was added 1 mL of 
Solvable
®
 and was incubated overnight at 25°C, and for 2 hr in a 60°C shaking water bath.  
To decolorize the samples, 100 µL of 0.1M EDTA was added followed by 200 µL of 30% 
H2O2 and the samples incubated for 30 min in a shaking water bath at 60°C.  After cooling to 
25°C, 10 mL of Ultima Gold scintillation cocktail was added to each vial and the 
radioactivity was measured using a Packard Tricarb scintillation counter and reported in 
DPM.  Organ-specific quench curves were generated but were found to be unnecessary as no 
quenching was observed; no correction for organ residual blood volume was performed.   
4.3.3 CT26 Tumor Growth Study 
Thirty female Balb/c mice, age 8-10 weeks, were subcutaneously inoculated with 2.5 
x 10
5
 syngeneic CT26 cells in 50 µL HBSS into the right flank.  After 10 days the mice were 
randomly divided into three groups and treatment was initiated. The mice received a total of 
4 tail vein iv injections every 3 days.  Group A (N = 9) received 100 µl of PBS, group B (N = 
10) received 100 µg of CpG-COOH in 100 µl PBS, and group C (N = 10) received 100 µg of 
CpG-mal in 100 µl of PBS.   
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4.3.4 4T1 Tumor Growth Study 
Forty mice were orthotopically inoculated with 1 x 10
4
 4T1 cells in 50 µL PBS into 
the mammary fat pad.  After 10 days, the mice were randomly divided into three groups of 
10 and experimental treatments were initiated.  A total of three treatments were given every 
three days.  Group A received 100 µg of CpG in 100 µL PBS via tail vein, group B received 
50 µg of CpG in 50 µL PBS peritumorally, and group C received 100 µg equivalent of CpG-
mal in 100 µL PBS via tail vein.  All treatments were sterile filtered through a 0.22 µm 
PVDF filter immediately prior to injection.   
4.4 Results 
4.4.1 In Vitro Macrophage Activation 
It was shown previously that CpG-albumin conjugates display lower IL-12 and IL-6 
release from a macrophage cell line than unconjugated control CpG (Figure 3.6).  In order to 
test whether steric hindrance was inhibiting the CpG-albumin from interacting with TLR9, 
CpG was derivatized with a longer crosslinker containing 24 repeating ethylene glycol units, 
shown in Figure 4.2.  This chemical manipulation should extend the CpG moiety away from 
the albumin.  As shown in Figure 4.2 this modification did not increase the activation to any 
appreciable extent.  Additionally, in order to test whether releasing the CpG from albumin in 
the reductive environment of the endosome could increase the activity, a reversible disulfide 
crosslinker was employed to create a reducible linkage between CpG and albumin.  The 
disulfide was able to be reductively cleaved by dithiothreitol, indicating its instability in a 
reductive environment (data not shown).  However, the CpG-SS-albumin was still unable to 
increase the IL-12 or IL-6 secretion.   
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4.4.2 Pharmacokinetics and Biodistribution 
The maleimide modification was able to alter the plasma pharmacokinetics of CpG; 
as expected the [
3
H]-CpG-COOH that cannot form an adduct with albumin was rapidly 
cleared from the circulation and distributed into tissues whereas the [
3
H]-CpG-mal was more 
slowly distributed as shown in Figure 4.3.  Both of the CpG show biphasic plasma profiles 
indicating distribution into tissue compartments, most likely due to PS ODN have binding to 
numerous cell membrane proteins.(Beltinger, Saragovi et al., 1995)   
The biodistribution of the [
3
H]-CpG-mal was different than [
3
H]-CpG-COOH and can 
be seen in Figure 4.5.  The major difference was found in the liver and kidney.  For [
3
H]-
CpG-COOH the kidney had the highest accumulation of drug, whereas for [
3
H]-CpG-mal the 
liver had the highest accumulation.  The spleen also had higher accumulation for [
3
H]-CpG-
mal than [
3
H]-CpG-COOH.  The tumor accumulation of [
3
H]-CpG-mal is presented in 
Figure 4.4 and was slightly increased compared to [
3
H]-CpG-COOH.  There is a clear 
downward trend for [
3
H]-CpG-COOH tumor concentration from 1-4 h, whereas the [
3
H]-
CpG-mal is increasing during this time. 
4.4.3 Tumor Growth Studies 
In the CT26 model, a dramatic difference was seen between the groups receiving 
CpG therapy and the PBS group, and little difference was observed between the CpG-COOH 
and CpG-mal groups.  The mice treated with CpG-COOH and CpG-mal showed a slow 
increase in tumor size during treatment followed by a complete regression in tumor volume.  
When the individual mice tumor volumes are examined in Figure 4.8 it is evident that there 
are clear-cut responders and non-responders to the CpG monotherapy.  There also appears to 
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be slightly more variability in the response to the CpG-COOH compared to CpG-mal.  On 
the other hand, in Figure 4.6 the 4T1 model the tumor growth was only slowed during 
treatment, and when treatment was stopped the tumors quickly began to grow.  Additionally, 
severe toxicity was observed after the second treatment for both of the systemically-injected 
treatments in this model.   
4.5 Discussion 
Figure 4.2 demonstrates CpG-albumin conjugates are able to activate the immune 
system, presumably via TLR9, albeit to a weaker extent than free CpG.  The length of the 
crosslinker did not have a significant effect on the in vitro activation of macrophages, 
suggesting steric hindrance by the conjugated albumin does not interfere with TLR9 
signaling.  Incorporation of a reversible disulfide bond should generate free CpG if the bond 
is reduced.  This should increase the activation of the macrophages to levels comparable to 
free CpG.  The observation that the reducible disulfide crosslinker was not able to increase 
the in vitro activation is most likely explained by the crosslinker not being biologically 
reduced during the timeframe of TLR9 signaling.  This is in contrast to a study that linked 
CpG to an antibody using a disulfide linkage and found that a cleavable linker was needed 
for immune cell activation.  It should be noted that study used a 5’ conjugated CpG which is 
known to reduce the activation(Kandimalla, Bhagat et al., 2002), additionally, in their in vitro 
incubation experiments the media was supplemented with β-mercaptoethanol, which could 
have provided an artificial reductive environment.(Sharma, Dominguez et al., 2008)  
Whether our observation can be extended to other phagocytic cell types, or if the in vivo 
redox state is faithfully mimicked in vitro, remains to be seen.  However, if so, it suggests 
that reduction would need to occur prior to internalization.  The difference in activation may 
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well be due to a difference in the internalization mechanism between the CpG-albumin 
versus free CpG.   
Our results are in agreement with the observation that the maleimide group is 
compatible with phoshpohthiote ODN.(Sanchez, Pedroso et al., 2012)  The plasma half-life 
of CpG ODN was altered by the conjugation of a maleimide group which allowed the CpG-
mal to covalently react with circulating albumin.  Since the plasma clearance represents 
distribution rather than elimination the CpG-mal which has distributed out of the vasculature 
prior to albumin conjugation may still react with the interstitial albumin.  After conjugation, 
the CpG-albumin displayed a slower plasma distribution, as would be predicted with an 
increase in hydrodynamic size.  Also consistent with this finding is the observation that the 
kidney accumulation was reduced for the CpG-mal compared to CpG-COOH.  The addition 
of the 3’ amino modification and subsequent conjugation with EMCS is not expected to 
dramatically alter the distribution of CpG.  In another study where a PS ODN was modified 
with a 5’ octadecyl-amine moiety, the distribution and clearance was marginally 
altered.(Crooke, Graham et al., 1996)   
Interestingly, the liver accumulation of CpG-mal was significantly increased 
compared to CpG-COOH.  This may be due to the fact that the plasma half-life was 
increased, promoting more interaction with richly-perfused liver tissue.  Since the liver 
accumulation was not rapid, it does not appear to involve high-affinity scavenger receptors 
that are thought to specifically bind degraded albumin.(Schnitzer and Bravo, 1993)  The liver 
uptake is not expected to be saturated at the doses of CpG that were administered in this 
study.(Graham, Crooke et al., 1998)  Also, the large amount of liver uptake appears to be 
inherent to phosphorothioate ODN as it is not seen with phosphodiester ODN.(Sands, Gorey-
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Feret et al., 1994)  The slight increased spleen uptake could lead to an increase in efficacy 
due to the high amount of antigen presenting cells in this organ.  Alternatively, the increased 
uptake by the spleen and liver could lead to non-specific systemic immune response which 
may have caused the increase in toxicity observed in the 4T1 study.(Martin-Armas, Simon-
Santamaria et al., 2006)   
The difference in tumor accumulation was less striking than would be predicted based 
on the difference in plasma concentration.  Again, we attribute this to the high liver clearance 
of the CpG-mal.  Additionally, CpG-mal had a slightly increased tumor accumulation 
compared to CpG-COOH and it appears the tumor retention was also increased. This increase 
in exposure may account for the less variable response of the CpG-mal compared to CpG-
COOH in the CT26 tumor model. 
The efficacy of CpG therapy was found to be dependent on the tumor model.  In the 
CT26 model tumor regression was observed, whereas no regression was seen in the 4T1 
model.  Since CpG is not inherently cytotoxic, the only way for there to be delayed 
regression in tumor volume would be if an adaptive immune response involving mostly 
CD8+ cytotoxic lymphocytes against the tumor was generated.  The fact that there was 
observed regression in the CT26 model suggests a specific immune response was generated.  
This is supported by the finding that the CT26 model is known to be moderately 
immunogenic(Belnap, Cleveland et al., 1979), whereas the 4T1 model is non-
immunogenic.(Pulaski and Ostrand-Rosenberg, 1998)  Only studies which tested a 
combination of CpG with an apoptosis-inducing component were found to be successful in 
the 4T1 model.(Mroz, Castano et al., 2009; Shirota and Klinman, 2011)  Clearly the need for 
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tumor-associated antigens is critical for CpG therapy, as well as for all adjuvant 
immunotherapies in general. 
It has been reported that tumor burden when CpG therapy is initiated determines the 
efficacy, with small tumors showing a better response.(Heckelsmiller, Rall et al., 2002; 
Sharma, Karakousis et al., 2004)  The tumor size in the current study was intermediate 
compared to these previous studies but there was no correlation in the current study between 
the initial size at treatment and the non-responders.  Unexpectedly, CpG-COOH was also 
found to be efficacious when administered systemically.  This may be explained by the 
dosing schedule used in the current study, administering the maximally-tolerated dose.  
Alternatively, this may be due to the differences in the activation of immune cells by CpG-
COOH versus CpG.  It is also interesting to note the difference in individual tumor growth 
patterns.  For the CpG-COOH, it appears the tumors had more variability in growth during 
treatment, whereas the CpG-mal had reliably more controlled growth.  This suggests there is 
a difference in the immediate cytokine release and NK cell activation.  Minimizing the tumor 
growth during treatment is clinically important especially if the comorbidities are associated 
with the tumor size.  
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Figure 4.1.  Chemical structures and synthetic scheme for the 
synthesis of CpG-mal and CpG-COOH.    
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Figure 4.2.  In vitro IL-12 and IL-6 release from CpG-albumin conjugates.The chemical structures of the different 
CpG-mal to prepare CpG-albumin conjugates are shown.  It does not appear that the activtion of the macrophages is 
sensitive to the crosslinker. 
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Figure 4.3.  Blood concentration of [
3
H]-CpG.  The CpG-
mal exhibits much less initial distribution than CpG-
COOH.  The lines represent the 2-compartment model 
parameters in Table 4-1 fit to the data.  For each 
timepoint 3 mice were sacrificed.  The error bars 
represent the standard deviation.   
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Table 4-1.  Two-compartment model parameters for [
3
H]-labeled CpG.   
 V1 
(mL) 
k10 
(h
-1
) 
k12 
(h
-1
) 
k21 
(h
-1
) 
[
3
H]-CpG-COOH 3.8 ± 1.4 4.0 ± 1.5 5.6 ± 1.0 1.5 ± 0.8 
[
3
H]-CpG-mal 2.7 ± 0.3 0.3 ± 0.02 0.9 ± 0.2 0.08 ± 0.04 
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Figure 4.4.  Tumor accumulation of PS [
3
H]-CpG.  The 
tumor accumulation appears to quickly saturate for both 
treatments.  There is a clear downward trend for CpG-
COOH between 1-4 h whereas, the CpG-mal is increasing 
during this time.  .  For each timepoint 3 mice were 
sacrificed.  The error bars represent the standard deviation.   
 
 
 
 
  
0
2
4
6
8
10
0 10 20 30 40
Tu
m
o
r 
C
o
n
ce
n
tr
at
io
n
 (
µ
g/
g 
ti
ss
u
e
) 
Time (h) 
CpG-COOH
CpG-MAL
84 
 
 
 
Figure 4.5.  Biodistribution of [
3
H]-labeled CpG. For the 
CpG-COOH, each bar represents data from each of the 
following timepoints: 5, 10, 15, 30, 60, 120, 240 min.  For 
CpG-mal, each bar represents data for the following 
timepoints:  10 min, 1, 4, 8, 15, 24, 40 h.  Each timepoint 
is the average concentration calculated from 3 mice and 
the error bars represent the standard deviation. 
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Figure 4.6.  Tumor growth inhibition of 4T1 tumors.  
The growth appears to be slowed during treatment but 
promptly resumes after the last dose.  N=4 for CpG (iv); 
N=10 for CpG (pt); N=3 for CpG-mal (iv); and N = 7 for 
untreated.  Severe toxicity was observed in this model for 
both systemically injected treatments.   
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Figure 4.7.  CT26 tumor growth curves.  Both CpG-
COOH and CpG-mal caused marked tumor growth 
reduction compared to PBS.  Four total treatments were 
given starting day 10 every 3 days.  
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Figure 4.8.  Individual growth curves for CT26 tumors.  
There were clear responders and non-responders to both 
treatments.  The CpG-mal has less variability in growth 
during treatment.  The arrows represent treatments.   
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 CHAPTER V: CONCLUSIONS & FUTURE DIRECTION 
 
 
The goal of this dissertation was to determine if serum albumin had potential utility as 
a carrier of CpG for cancer therapy.  The collective results support the notion that albumin 
may have a utility, albeit limited, in this narrowly-defined scope.   
CpG oligodeoxynucleotide (ODN) was modified with maleimide groups to allow an 
in situ reaction with Cys34 of serum albumin.  For phosphodiester (PO) CpG, PET/CT 
imaging was used to determine the pharmacokinetics and biodistribution (PK/BD) of 
124
I-
labeled CpG-mal.  The in situ reaction with albumin was determined to be complete within 
minutes and was sufficient to compete with the rapid plasma clearance in vivo.  The plasma 
half-life and tumor accumulation were increased compared to control CpG-COOH that is 
unable to react with albumin.  Despite this increase in tumor exposure, the PO CpG-mal was 
not efficacious in the 4T1 cancer model at inhibiting tumor growth, increasing survival, or 
decreasing the number of lung metastasis.  Subsequent in vitro activation of macrophages 
indicated that PO CpG is not a potent agonist of TLR9 which was attributed instability to 
endogenous nucleases.  Since the amount of cellular uptake was not directly measured in the 
in vitro experiments it is unknown if a difference in uptake could account for the reduction in 
cytokine release.  Further experiments should be done to elucidate if any differences in in 
vitro uptake is observed.   
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In contrast to PO CpG, the PS CpG was able to significantly increase the TLR9 
activation and subsequent release of IL-6 and IL-12 in vitro.  Conjugation of the PS CpG to 
albumin reduced, but did not abolish, the activation.  The reduction in activation is not 
believed to be caused by steric hindrance of albumin because increasing the crosslinker 
length did not increase the activation.  Additionally, adding a reducible disulfide linker did 
not increase the activation, which suggests biological reduction did not happen within the 
timeframe of TLR9 signaling.  This may support the notion that endosomes are not 
sufficiently reductive environments for reducing disulfide bonds.   
Tumor growth inhibition studies using the 4T1 model and PS CpG showed a slowing 
of tumor growth during treatment, but after treatment was stopped the tumor growth 
resumed.  Additionally, severe toxicity was seen in this aggressive model which was 
attributed to an additive effect of the metastatic spread and the induced inflammatory 
response.  The lack of efficacy in this model was attributed to the lack of shedding of tumor 
antigens as the 4T1 is known to be inherently non-immunogenic.(Pulaski and Ostrand-
Rosenberg, 1998) 
The physicochemical properties of PS CpG are different than PO CpG and 
extrapolation of the PK/BD results for the PO CpG to PS CpG is tenuous.  Attempts to 
radiolabel the PS CpG with 
124
I were not successful, therefore a tritium label was used to 
monitor the PK/BD of PS [
3
H]-CpG-mal.  The plasma half-life of the PS CpG-mal was 
increased compared to control CpG, but the increase was not as striking as for PO CpG.  This 
is due to the high liver accumulation of PS CpG-mal which was not observed for PO CpG-
mal.  The accumulation in the liver was not immediate, but sustained, and reached 
approximately 50 µg/g tissue at 4 h.  This rules out high-affinity scavenger receptors which 
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quickly remove highly modified albumin, but it may indicate low-affinity scavenger 
receptors that can remove partially-modified albumin.(Stehle, Sinn et al., 1997)  In support of 
this is the fact that highly anionic substrates are usually taken up by scavenger receptors 
located on macrophages and liver sinusoidal endothelial cells.(Yamasaki, Hisazumi et al., 
2003)  Conjugation of the CpG to albumin is expected to roughly double the amount of 
negative charge, rendering the conjugate a better substrate for these receptors.  Although, 
conjugation of PO CpG is expected to also increase the negative charge. 
Unfortunately, this high liver accumulation reduces the tumor exposure.  Future 
studies should investigate the nature of this uptake.  Is it due to receptors specific for PS 
ODN, or is it due to albumin scavenger receptors recognizing the PS CpG-albumin conjugate 
as degraded albumin?  This could be tested by adding a competitor of these receptors and 
seeing if the uptake is reduced.  However, both receptors share an overlap in inhibitors, so a 
specific inhibitor without a monoclonal antibody would be difficult to employ.  Even so, 
knowing the mechanism of liver uptake does not materially change the fact that it happens 
and it is a significant limitation for the therapeutic potential of PS CpG.  If the uptake is 
determined to be caused by receptors recognizing the PS CpG, then reducing the length of 
the CpG may reduce the affinity towards these receptors, although this may also reduce the 
TLR9 affinity as well.  Another option is to use chimeric CpG which contains both PS and 
PO backbone which should reduce the non-specific interactions caused by the PS.  But this 
also may have nuclease instability due to the presence of endonucleases that can cleave the 
PO bonds.(Boado, Kang et al., 1995)  It may also be possible for future CpG chimeras that 
have other backbone modifications to be used as well.   
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Interestingly, the tumor appears to quickly accumulate PS CpG, which may be due to 
some type of binding process to cellular targets.(Beltinger, Saragovi et al., 1995)  The tumor 
concentration for CpG-mal also quickly reaches close to maximal level, but still shows an 
increase in tumor accumulation with time.  This increase stems from the increased half-life of 
the CpG-albumin conjugate in the circulation.  In both biodistribution experiments the tumor 
concentration reached a maximal value of approximately 3-6 %ID/g tissue.  Since the 
average mice body weight used in the studies was approximately 18-20 g, it appears that on a 
per-weight basis selective accumulation in the tumor was minimal.   
The antitumor effects of CpG-mal and CpG-COOH were clearly observed in the 
CT26 colon cancer model.  Both treatments showed a remarkable reduction in growth rate 
during treatment, and between 6-10 days after the first treatment the tumors began to regress.  
This timeline is consistent with the expected activation and infiltration of CD8+ T cells.  
Examination of the individual tumor growth curves suggest 6/10 mice had full regression of 
the tumors while the others had stasis or partial regression following by rapid regrowth of the 
tumors suggesting a lack of an adaptive immune response.  These results are typical of nearly 
all immunotherapies and were even observed in Dr. Coley’s initial experiments.   
The increased retention by the tumor of CpG-mal compared to CpG-COOH suggests 
that decreasing the dose or dosing frequency may magnify the difference in the efficacy 
between the two treatments.  This could be tested in future dose-response studies, where a 
clinical response may still be observed with less frequent or lower dose injections for CpG-
mal but not CpG-COOH. 
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The immune response in the tumor microenvironment is delicate and sometimes 
activation of the immune system can increase the growth rate of tumors and increase the 
chance of metastasis.(DeNardo, Barreto et al., 2009)  Therefore, the manner in which the 
immune system is manipulated in the tumor microevironment is critically important.  The 
fact that we noticed different cytokine release patterns for CpG-albumin compared to free 
CpG could have a dramatic effect on the nature of the local immune response.  This is 
indicated by the more controlled growth observed in Figure 4.8.  In future studies, a wider 
variety of cytokines could be measured to determine the differences in activation between the 
CpG-albumin and free CpG.   
The tumor growth inhibition assay, while clinically important, is a crude measure of 
efficacy.  Cellular mechanistic studies should be investigated in future experiments.  The 
most important measure of efficacy is the infiltration of tumor-specific CD8+ T cells.  Flow 
cytometry could be performed on single cells suspensions of excised tumors to determine the 
percentage of CD8+ T cells in the tumor.  Additionally, dendritic cells from the tumor-
draining lymph nodes could be cultured and stimulated with tumor homogenates and the 
expression of activation markers could be quantified by flow cytometry.   
Long-term toxicity was not assayed during the current studies, but it does not appear 
that conjugation of the CpG to albumin caused a catastrophic immune response to albumin.  
The fact that CpG-albumin is present in the circulation for longer times in an active form is 
not inherently a problem.  It is known that circulating monocytes and dendritic cells have a 
reduced phagocytic rate compared to peripheral tissue phagocytic cells.  This should reduce 
their uptake of the active CpG-albumin conjugate.   
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CpG has been conjugated to antigens in order to increase accumulation of the CpG 
and the antigen in the same antigen presenting cell in order to encourage cross-
presentation.(Maurer, Heit et al., 2002)  In our case though, albumin is not an antigen and an 
immune response to albumin would be highly undesirable.  Many studies have synthesized 
albumin fusion proteins with various cytokines and have not seen deleterious immune 
responses against albumin in preclinical settings; their clinical safety is under 
investigation.(Chang, Gupta et al., 2009)  Conceptually, it is more probable that if an 
immune response were to be generated it would be against the crosslinker or the CpG rather 
than native albumin.  Since the PK experiments were only determined for the first dose, the 
results would not be expected to be influenced by a generated immune response.  In order to 
test this, PK after multiple dosing should be performed.  If an immune response is generated 
against the CpG-albumin conjugate, then the clearance should be expected to be increased.   
Since maleimide is not selective to which thiols they react with, any exposed thiols 
are subject to reaction.  N-ethylmaleimide (NEM) has been used to study enzyme inhibition 
and has been shown to be toxic.(Schoonen, De Roos et al., 2005)  However, NEM is 
considerably smaller and more hydrophobic so it readily diffuses into cell membranes and 
has access intracellular proteins and enzymes with catalytic thiol residues.  The CpG-mal is 
not expected to readily diffuse through plasma membranes and will not have access to these 
intracellular thiols.  This restricted distribution should dramatically reduce the maleimide-
related toxicity.   
One potential drawback of using endogenous albumin as a carrier for anticancer drugs 
is that cancer patients have reduced concentrations of serum albumin.  This limits the amount 
of carrier protein present at any given time.  Additionally, during an acute immune response, 
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the transcription of albumin is known to be transiently reduced.(Liao, Jefferson et al., 1986)  
This may limit the amount of albumin available for future dosing.  Nevertheless, albumin 
should be in a 10 fold excess compared to CpG-mal at the administered concentration.   
 Conjugation to albumin does not appear to abolish interaction with extracellular or 
endosomal targets based off the observations that CpG-albumin was degraded by plasma 
nucleases and able to activate macrophages by TLR9 signaling.  This suggests that albumin 
could be used as a carrier for any therapeutic whose target is accessible to native albumin, 
which includes any surface, extracellular, or endosomal targets but would not include any 
intracellular or nuclear targets.  This no doubt limits the therapeutic opportunities but still 
leaves significant number of targets which could be improved by albumin conjugation.  In 
summary, the use of albumin as a carrier for CpG may be limited, but that does not rule out 
other potential therapeutics that could benefit from albumin conjugation. 
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 APPENDIX A 
 
 
Included in the appendix are the NMR spectra and m/s analysis for the crosslinker 
synthesized in Chapter II.   
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Figure A.1.  
1
H NMR spectrum of Mal-Tyr(tBu)-OtBu (1) 
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Figure A.2.  
13
C NMR of Mal-Tyr(tBu)-OtBu (1) 
103 
 
Figure A.3.  
1
H NMR of Mal-Tyr (2) 
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Figure A.4.  
13
C NMR of Mal-Tyr (2) 
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Figure A.5.  Mass Spectrum of Mal-Tyr (2) 
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Figure A.6.  
1
H NMR spectrum of Mal-Tyr-TEG-COOH (3) 
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Figure A.7.  
13
C NMR spectrum of Mal-Tyr-TEG-COOH (3) 
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Figure A.8.  Mass spectrum of Mal-Tyr-TEG-COOH (3) 
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Figure A.9.  
1
H NMR of Mal-Tyr-TEG-NHS (4) 
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Figure A.10.  
13
C NMR of Mal-Tyr-TEG-NHS (4) 
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Figure A.11.  Mass spectrum of Mal-Tyr-TEG-NHS (4) 
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Figure A.12.  Deconvoluted mass spectrum of ODN-mal.   
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